Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 1156 articles:
HTML format



Single Articles


    September 2020
  1. XUE L, Chen F, Yue F, Camacho L, et al
    Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05927.
    PubMed     Abstract available


  2. DENT SF, Botros J, Rushton M, Aseyev O, et al
    Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05887.
    PubMed     Abstract available


  3. LOSK K, Freedman RA, Laws A, Kantor O, et al
    Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05931.
    PubMed     Abstract available


  4. WANG B, Huang T, Fang Q, Zhang X, et al
    Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05904.
    PubMed     Abstract available


  5. VAN NIJNATTEN TJA, van Tiel LPT, Voogd AC, Groothuis-Oudshoorn CGM, et al
    The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05906.
    PubMed     Abstract available


  6. GOLDFARB SB, Turan V, Bedoschi G, Taylan E, et al
    Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05933.
    PubMed     Abstract available


  7. PALLESCHI M, Scarpi E, Casadei C
    Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05923.
    PubMed    


  8. MONTAGNA E, Pagan E, Bagnardi V, Colleoni M, et al
    Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05900.
    PubMed     Abstract available


  9. HAN Y, Miao ZF, Lian M, Peterson LL, et al
    Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05902.
    PubMed     Abstract available


  10. KOU K, Cameron J, Aitken JF, Youl P, et al
    Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05905.
    PubMed     Abstract available


  11. ABDELHAFEZ AH, Musall BC, Adrada BE, Hess K, et al
    Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05917.
    PubMed     Abstract available


  12. TAKAHASHI M, Ohtani S, Nagai SE, Takashima S, et al
    The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05921.
    PubMed     Abstract available


  13. MENEVEAU MO, Keim-Malpass J, Camacho TF, Anderson RT, et al
    Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05908.
    PubMed     Abstract available


  14. FRISELL A, Lagergren J, Halle M, de Boniface J, et al
    Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05911.
    PubMed     Abstract available


  15. VOGSEN M, Jensen JD, Christensen IY, Gerke O, et al
    FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05929.
    PubMed     Abstract available


  16. LIN Y, Lin L, Fu F, Wang C, et al
    Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05916.
    PubMed     Abstract available


  17. YUSUFOV M, Nathan M, Wiley A, Russell J, et al
    Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05920.
    PubMed     Abstract available


  18. MAO D, Hachem H, Chang H, Dima D, et al
    Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05892.
    PubMed     Abstract available


  19. CALIP GS, Kidd J, Bernhisel R, Cox HC, et al
    Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    Breast Cancer Res Treat. 2020 Sep 11. pii: 10.1007/s10549-020-05922.
    PubMed     Abstract available


  20. HISOSHIMA M, Urano M, Ohashi K, Ogawa M, et al
    Utility of 70-kV single-energy CT in depicting the extent of breast cancer for preoperative planning.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05909.
    PubMed     Abstract available


  21. XING CY, Doose M, Qin B, Lin Y, et al
    Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05901.
    PubMed     Abstract available


  22. YANG Y, Zhao J, Mao Y, Lin G, et al
    UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing beta-catenin.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05899.
    PubMed     Abstract available


  23. SOLLENA P, Nikolaou V, Soupos N, Kotteas E, et al
    Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05914.
    PubMed     Abstract available


  24. LEE KT, Jacobs L, Walsh EM, Stearns V, et al
    Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05910.
    PubMed     Abstract available


  25. DE REZENDE LF, Francisco VE, Franco RL
    Telerehabilitation for patients with breast cancer through the COVID-19 pandemic.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05926.
    PubMed    


  26. CHA C, Lee J, Kim D, Park S, et al
    Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Sep 9. pii: 10.1007/s10549-020-05907.
    PubMed     Abstract available


  27. SUN Y, Li Y, Wu J, Tian H, et al
    Nomograms for prediction of overall and cancer-specific survival in young breast cancer.
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05870.
    PubMed     Abstract available


  28. CHEN R, Ma G, Xia T
    Letter to the editor with regard to the manuscript titled "Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy".
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05886.
    PubMed    


  29. KO NY, Qureshi MM, Oladeru OT, Cassidy MR, et al
    Racial differences in genomic testing and receipt of endocrine therapy in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 4. pii: 10.1007/s10549-020-05888.
    PubMed     Abstract available


  30. ZHANG Y, Liu J, Raj-Kumar PK, Sturtz LA, et al
    Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05884.
    PubMed     Abstract available


  31. GONZALEZ-SANTIAGO S, Saura C, Ciruelos E, Alonso JL, et al
    Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05866.
    PubMed     Abstract available


  32. SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
    Risk factors for inflammatory and non-inflammatory breast cancer in North Africa.
    Breast Cancer Res Treat. 2020 Sep 2. pii: 10.1007/s10549-020-05864.
    PubMed     Abstract available


  33. NIETZ S, O'Neil DS, Ayeni O, Chen WC, et al
    A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.
    Breast Cancer Res Treat. 2020 Sep 1. pii: 10.1007/s10549-020-05889.
    PubMed     Abstract available


    August 2020
  34. LYNGE E, Beau AB, von Euler-Chelpin M, Napolitano G, et al
    Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark.
    Breast Cancer Res Treat. 2020 Aug 30. pii: 10.1007/s10549-020-05896.
    PubMed     Abstract available


  35. HOWELL SJ, Coe F, Wang X, Horsley L, et al
    Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
    Breast Cancer Res Treat. 2020 Aug 29. pii: 10.1007/s10549-020-05868.
    PubMed     Abstract available


  36. KIM JY, Park K, Im SA, Jung KH, et al
    Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
    Breast Cancer Res Treat. 2020 Aug 28. pii: 10.1007/s10549-020-05891.
    PubMed     Abstract available


  37. ERBER R, Rubner M, Davenport S, Hauke S, et al
    Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 27. pii: 10.1007/s10549-020-05865.
    PubMed     Abstract available


  38. PIZZATO M, Carioli G, Rosso S, Zanetti R, et al
    The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05820.
    PubMed     Abstract available


  39. HERMANN N, Klil-Drori A, Angarita FA, Westergard S, et al
    Screening women at high risk for breast cancer: one program fits all? : Subgroup analysis of a large population high risk breast screening program.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05895.
    PubMed     Abstract available


  40. SUNDBOLL J, Farkas DK, Adelborg K, Schapira L, et al
    Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Aug 26. pii: 10.1007/s10549-020-05879.
    PubMed     Abstract available


  41. TRANT AA, Walz L, Allen W, DeJesus J, et al
    Increasing accrual of minority patients in breast cancer clinical trials.
    Breast Cancer Res Treat. 2020 Aug 25. pii: 10.1007/s10549-020-05873.
    PubMed     Abstract available


  42. OGIYA R, Niikura N, Kumamaru H, Takeuchi Y, et al
    Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study.
    Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05869.
    PubMed     Abstract available


  43. RIEDEL F, Heil J, Feisst M, Moderow M, et al
    Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Breast Cancer Res Treat. 2020 Aug 20. pii: 10.1007/s10549-020-05876.
    PubMed     Abstract available


  44. DE BOER AZ, van de Water W, Bastiaannet E, de Glas NA, et al
    Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.
    Breast Cancer Res Treat. 2020 Aug 19. pii: 10.1007/s10549-020-05860.
    PubMed     Abstract available


  45. KIM JY, Jung HH, Sohn I, Woo SY, et al
    Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05874.
    PubMed     Abstract available


  46. KILBREATH SL, Ward LC, Davis GM, Degnim AC, et al
    Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled exercise trial.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05863.
    PubMed     Abstract available


  47. DIXON JM, Grewar J, Twelves D, Graham A, et al
    Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05843.
    PubMed     Abstract available


  48. BAGHERZADEH M, Szymiczek A, Donenberg T, Butler R, et al
    Association of RAD51C germline mutations with breast cancer among Bahamians.
    Breast Cancer Res Treat. 2020 Aug 18. pii: 10.1007/s10549-020-05872.
    PubMed     Abstract available


  49. KAZMI S, Chatterjee D, Raju D, Hauser R, et al
    Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05867.
    PubMed     Abstract available


  50. TEODOZIO CGC, Marchito LO, Fabro EAN, Macedo FO, et al
    Shoulder amplitude movement does not influence postoperative wound complications after breast cancer surgery: a randomized clinical trial.
    Breast Cancer Res Treat. 2020 Aug 17. pii: 10.1007/s10549-020-05826.
    PubMed     Abstract available


  51. CAVALCANTE FP, Novita GG, Millen EC, Zerwes FP, et al
    Management of early breast cancer during the COVID-19 pandemic in Brazil.
    Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05877.
    PubMed     Abstract available


  52. BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, et al
    Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat. 2020 Aug 16. pii: 10.1007/s10549-020-05829.
    PubMed     Abstract available


  53. GEORGE MA, Lustberg MB, Orchard TS
    Psychoneurological symptom cluster in breast cancer: the role of inflammation and diet.
    Breast Cancer Res Treat. 2020 Aug 15. pii: 10.1007/s10549-020-05808.
    PubMed     Abstract available


  54. LIANG R
    Letter to the editor Re: Pan et al. "LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer".
    Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05853.
    PubMed    


  55. DIAMOND JR, Becerra C, Richards D, Mita A, et al
    Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Aug 14. pii: 10.1007/s10549-020-05817.
    PubMed     Abstract available


  56. BARTLETT DB, Broadwater G, White HK, Shelby R, et al
    Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic.
    Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05862.
    PubMed     Abstract available


  57. D'HONDT C, Vanhoeij M, Van Moer E, Segers I, et al
    Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Aug 13. pii: 10.1007/s10549-020-05858.
    PubMed     Abstract available


  58. RUGO HS, Dieras V, Cortes J, Patt D, et al
    Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
    Breast Cancer Res Treat. 2020 Aug 12. pii: 10.1007/s10549-020-05838.
    PubMed     Abstract available


  59. KANJANAPAN Y, Lok SW, Gibbs P, De Boer R, et al
    Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05825.
    PubMed     Abstract available


  60. CADY B, Fulton JP
    57% decline in Rhode Island invasive breast cancer mortality between 1987 and 2017: mammography predominates in preventing mortality.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05834.
    PubMed     Abstract available


  61. ZHANG Y, Dian L, Wei X, Huang J, et al
    Physicians' attitudes towards reproduction in young patients with early breast cancer in China.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05854.
    PubMed     Abstract available


  62. BI Z, Chen P, Liu YB, Zhao T, et al
    Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
    Breast Cancer Res Treat. 2020 Aug 10. pii: 10.1007/s10549-020-05851.
    PubMed     Abstract available


  63. SOKOLENKO AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, et al
    Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05827.
    PubMed     Abstract available


  64. CRYSTAL JS, Rand J, Johnson J, Kim S, et al
    Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05823.
    PubMed     Abstract available


  65. PAPAUTSKY EL, Hamlish T
    Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05828.
    PubMed     Abstract available


  66. TREVINO KM, Iyengar N, Li Q, Mao JJ, et al
    Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety.
    Breast Cancer Res Treat. 2020 Aug 9. pii: 10.1007/s10549-020-05859.
    PubMed     Abstract available


  67. CHEN J, Lai YH, Ooi S, Song Y, et al
    BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer.
    Breast Cancer Res Treat. 2020 Aug 8. pii: 10.1007/s10549-020-05857.
    PubMed     Abstract available


  68. SCHETTINI F, Sobhani N, Ianza A, Triulzi T, et al
    Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
    Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05856.
    PubMed     Abstract available


  69. WILLIAMS CB, Nebhan CA, Yang J, Starnes LS, et al
    Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
    Breast Cancer Res Treat. 2020 Aug 7. pii: 10.1007/s10549-020-05846.
    PubMed     Abstract available


  70. SALTBAEK L, Horsboel TA, Offersen BV, Andersson M, et al
    Patterns in detection of recurrence among patients treated for breast cancer.
    Breast Cancer Res Treat. 2020 Aug 6. pii: 10.1007/s10549-020-05847.
    PubMed     Abstract available


  71. PATEL MA, Shah JL, Abrahamse PH, Jagsi R, et al
    A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05844.
    PubMed     Abstract available


  72. ZHOU YT, Zheng LY, Wang YJ, Yang L, et al
    Effect of functional variant rs11466313 on breast cancer susceptibility and TGFB1 promoter activity.
    Breast Cancer Res Treat. 2020 Aug 5. pii: 10.1007/s10549-020-05841.
    PubMed     Abstract available


  73. SKRIVER SK, Jensen MB, Eriksen JO, Ahlborn LB, et al
    Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Aug 3. pii: 10.1007/s10549-020-05833.
    PubMed     Abstract available


  74. SPECHT M, Sobti N, Rosado N, Tomczyk E, et al
    High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis.
    Breast Cancer Res Treat. 2020;182:679-688.
    PubMed     Abstract available


  75. GAO W, Zeng Y, Fei X, Chen X, et al
    Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05842.
    PubMed     Abstract available


  76. ZEIDMAN M, Alberty-Oller JJ, Ru M, Pisapati KV, et al
    Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05809.
    PubMed     Abstract available


  77. AOYAGI K, Higuchi Y, Matsunaga S, Serizawa T, et al
    Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702).
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05835.
    PubMed     Abstract available


  78. JOONA TB, Digkas E, Wennstig AK, Nystrom K, et al
    Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05815.
    PubMed     Abstract available


  79. SANDERINK WBG, Strobbe LJA, Bult P, Schlooz-Vries MS, et al
    Minimally invasive breast cancer excision using the breast lesion excision system under ultrasound guidance.
    Breast Cancer Res Treat. 2020 Aug 1. pii: 10.1007/s10549-020-05814.
    PubMed     Abstract available


    July 2020
  80. HULL O, Niranjan SJ, Wallace AS, Williams BR, et al
    Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05832.
    PubMed     Abstract available


  81. HOTTON J, Salleron J, Henrot P, Buhler J, et al
    Pre-operative axillary ultrasound with fine-needle aspiration cytology performance and predictive factors of false negatives in axillary lymph node involvement in early breast cancer.
    Breast Cancer Res Treat. 2020 Jul 31. pii: 10.1007/s10549-020-05830.
    PubMed     Abstract available


  82. AL AMRI WS, Baxter DE, Hanby AM, Stead LF, et al
    Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.
    Breast Cancer Res Treat. 2020 Jul 30. pii: 10.1007/s10549-020-05836.
    PubMed     Abstract available


  83. AKS R, Peleg Hasson S, Sivan A, Kohen T, et al
    Diagnostic workup of early-stage breast cancer: can we choose more wisely?
    Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05813.
    PubMed     Abstract available


  84. ROSA DD, Bines J, Werutsky G, Barrios CH, et al
    The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).
    Breast Cancer Res Treat. 2020 Jul 29. pii: 10.1007/s10549-020-05831.
    PubMed     Abstract available


  85. CHAINITIKUN S, Long JP, Rodriguez-Bautista R, Iwase T, et al
    The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05837.
    PubMed     Abstract available


  86. HARDER H, Shilling VM, May SF, Cella D, et al
    The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 27. pii: 10.1007/s10549-020-05798.
    PubMed     Abstract available


  87. WANG L, He Y, Li J, Wang T, et al
    Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05821.
    PubMed     Abstract available


  88. ZHAO J, Meisel J, Guo Y, Nahta R, et al
    Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05819.
    PubMed     Abstract available


  89. KIM SH, Ahn S, Suh KJ, Kim YJ, et al
    Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
    Breast Cancer Res Treat. 2020 Jul 26. pii: 10.1007/s10549-020-05811.
    PubMed     Abstract available


  90. SMITH BL, Nguyen A, Korotkin JE, Kelly BN, et al
    A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry.
    Breast Cancer Res Treat. 2020 Jul 25. pii: 10.1007/s10549-020-05792.
    PubMed     Abstract available


  91. TAHIRI A, Tekpli X, Satheesh SV, DeWijn R, et al
    Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 24. pii: 10.1007/s10549-020-05763.
    PubMed     Abstract available


  92. DUDEK AZ, Liu LC, Fischer JH, Wiley EL, et al
    Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
    Breast Cancer Res Treat. 2020 Jul 22. pii: 10.1007/s10549-020-05787.
    PubMed     Abstract available


  93. KARLSSON F, Granath F, Smedby KE, Zedenius J, et al
    Sarcoma of the breast: breast cancer history as etiologic and prognostic factor-A population-based case-control study.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05802.
    PubMed     Abstract available


  94. CHEPIKOVA OE, Malin D, Strekalova E, Lukasheva EV, et al
    Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05801.
    PubMed     Abstract available


  95. YAP NY, Tan NYT, Tan CJ, Loh KW, et al
    Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05807.
    PubMed     Abstract available


  96. FASANO J, Shao T, Huang HH, Kessler AJ, et al
    Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05800.
    PubMed     Abstract available


  97. MINAMI CA, King TA, Mittendorf EA
    Patient preferences for locoregional therapy in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05737.
    PubMed     Abstract available


  98. SCHAIRER C, Laurent CA, Moy LM, Gierach GL, et al
    Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05785.
    PubMed     Abstract available


  99. BORTNIK S, Tessier-Cloutier B, Leung S, Xu J, et al
    Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05795.
    PubMed     Abstract available


  100. FINN RS, Boer K, Bondarenko I, Patel R, et al
    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
    Breast Cancer Res Treat. 2020 Jul 18. pii: 10.1007/s10549-020-05755.
    PubMed     Abstract available


  101. ARABANDI P, Slade AN, Sutton AL, McGuire KP, et al
    Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jul 16. pii: 10.1007/s10549-020-05784.
    PubMed     Abstract available


  102. MOFTAKHAR B, Lekkala M, Strawderman M, Smith TC, et al
    Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05793.
    PubMed     Abstract available


  103. REN H, Mi X, Zhao P, Zhao X, et al
    TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of beta-catenin.
    Breast Cancer Res Treat. 2020 Jul 15. pii: 10.1007/s10549-020-05789.
    PubMed     Abstract available


  104. HAM A, Kim MH, Kim GM, Kim JH, et al
    Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 14. pii: 10.1007/s10549-020-05796.
    PubMed     Abstract available


  105. BYRD BK, Krishnaswamy V, Gui J, Rooney T, et al
    The shape of breast cancer.
    Breast Cancer Res Treat. 2020 Jul 12. pii: 10.1007/s10549-020-05780.
    PubMed     Abstract available


  106. MCEVOY AM, Poplack S, Nickel K, Olsen MA, et al
    Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05768.
    PubMed     Abstract available


  107. MISRA S, Lee G, Korzets Y, Wang L, et al
    Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05781.
    PubMed     Abstract available


  108. SANT M, Meneghini E, Bastos J, Rossi PG, et al
    Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study.
    Breast Cancer Res Treat. 2020 Jul 10. pii: 10.1007/s10549-020-05761.
    PubMed     Abstract available


  109. DU ZL, Wang Y, Wang DY, Zhang L, et al
    Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
    Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05776.
    PubMed     Abstract available


  110. THEIN KZ, Htut TW, Ball S, Swarup S, et al
    Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of rand
    Breast Cancer Res Treat. 2020 Jul 9. pii: 10.1007/s10549-020-05783.
    PubMed     Abstract available


  111. ALTER BP, Best AF
    Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2020 Jul 8. pii: 10.1007/s10549-020-05775.
    PubMed     Abstract available


  112. STOCKER A, Trojan A, Elfgen C, Hilbers ML, et al
    Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 7. pii: 10.1007/s10549-020-05772.
    PubMed     Abstract available


  113. BORRIE AE, Rose FA, Choi YH, Perera FE, et al
    Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
    Breast Cancer Res Treat. 2020 Jul 6. pii: 10.1007/s10549-020-05777.
    PubMed     Abstract available


  114. WHITAKER KD, Sheth D, Olopade OI
    Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
    Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05759.
    PubMed     Abstract available


  115. CRISCITIELLO C, Vingiani A, Maisonneuve P, Viale G, et al
    Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
    Breast Cancer Res Treat. 2020 Jul 3. pii: 10.1007/s10549-020-05771.
    PubMed     Abstract available


  116. WALTER V, Fischer C, Deutsch TM, Ersing C, et al
    Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jul 1. pii: 10.1007/s10549-020-05746.
    PubMed     Abstract available


    June 2020
  117. GUO D, Hendryx M, Liang X, Manson JE, et al
    Association between selenium intake and breast cancer risk: results from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Jun 30. pii: 10.1007/s10549-020-05764.
    PubMed     Abstract available


  118. WANG DG, Barrios DM, Blinder VS, Bromberg JF, et al
    Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05726.
    PubMed     Abstract available


  119. KHALEFA HG, Shawki MA, Aboelhassan R, El Wakeel LM, et al
    Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05762.
    PubMed     Abstract available


  120. YANG X, Zhao L, Pei J, Wang Z, et al
    CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05753.
    PubMed     Abstract available


  121. CHEN FM, Huang LJ, Ou-Yang F, Kan JY, et al
    Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05729.
    PubMed     Abstract available


  122. DONAHUE PMC, Crescenzi R, Lee C, Garza M, et al
    Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema.
    Breast Cancer Res Treat. 2020 Jun 29. pii: 10.1007/s10549-020-05765.
    PubMed     Abstract available


  123. PERACHINO M, Poggio F, Lambertini M
    Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
    Breast Cancer Res Treat. 2020 Jun 28. pii: 10.1007/s10549-020-05767.
    PubMed    


  124. YAO J, Liu Y, Cheng J
    Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China.
    Breast Cancer Res Treat. 2020 Jun 27. pii: 10.1007/s10549-020-05743.
    PubMed     Abstract available


  125. ACCORDINO MK, Wright JD, Buono D, Lin A, et al
    Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05756.
    PubMed     Abstract available


  126. HACKSHAW MD, Danysh HE, Singh J, Ritchey ME, et al
    Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05754.
    PubMed     Abstract available


  127. CAVAZZA M, Banks H, Ercolanoni M, Cukaj G, et al
    Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Breast Cancer Res Treat. 2020 Jun 26. pii: 10.1007/s10549-020-05748.
    PubMed     Abstract available


  128. STASZEWSKY L, Robusto F, Lepore V, Bisceglia L, et al
    Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.
    Breast Cancer Res Treat. 2020 Jun 25. pii: 10.1007/s10549-020-05758.
    PubMed     Abstract available


  129. HAM A, Kim MH, Kim GM, Kim JH, et al
    Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05750.
    PubMed     Abstract available


  130. STARKINGS R, Shilling V, Jenkins V, Fallowfield L, et al
    A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05741.
    PubMed     Abstract available


  131. VERMA R, Hanby AM, Horgan K, Verghese ET, et al
    Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05757.
    PubMed     Abstract available


  132. WEI Y, Wang X, Zhang Z, Zhao C, et al
    Impact of NR5A2 and RYR2 3'UTR polymorphisms on the risk of breast cancer in a Chinese Han population.
    Breast Cancer Res Treat. 2020 Jun 23. pii: 10.1007/s10549-020-05736.
    PubMed     Abstract available


  133. ROBERTSON S, Acs B, Lippert M, Hartman J, et al
    Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05752.
    PubMed     Abstract available


  134. HARBORG S, Heide-Jorgensen U, Ahern TP, Ewertz M, et al
    Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05749.
    PubMed     Abstract available


  135. HORIMOTO Y, Sasahara N, Sasaki R, Hlaing MT, et al
    High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jun 22. pii: 10.1007/s10549-020-05751.
    PubMed     Abstract available


  136. XU B, Li W, Zhang Q, Shao Z, et al
    Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05728.
    PubMed     Abstract available


  137. CHENG AS, Leung SCY, Gao D, Burugu S, et al
    Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jun 20. pii: 10.1007/s10549-020-05745.
    PubMed     Abstract available


  138. CHAMBERLIN MD, Wells JD, Shee K, Bean JR, et al
    Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05714.
    PubMed     Abstract available


  139. HOWLADER NR, Rahman MM, Hossain MA, Sultana R, et al
    Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05738.
    PubMed     Abstract available


  140. KAR A, Koto K, Walker D, Trudeau T, et al
    ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR(+)HER2(+) breast cancer patients.
    Breast Cancer Res Treat. 2020 Jun 19. pii: 10.1007/s10549-020-05734.
    PubMed     Abstract available


  141. BESIC N, Smrekar J, Strazisar B
    Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study.
    Breast Cancer Res Treat. 2020 Jun 18. pii: 10.1007/s10549-020-05713.
    PubMed     Abstract available


  142. OBENG-GYASI S, Oppong B, Paskett ED, Lustberg M, et al
    Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?
    Breast Cancer Res Treat. 2020 Jun 16. pii: 10.1007/s10549-020-05740.
    PubMed     Abstract available


  143. AHMED M
    The bottom line for lesion localization in breast cancer.
    Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05735.
    PubMed     Abstract available


  144. TOLLOSA DN, Holliday E, Hure A, Tavener M, et al
    A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer.
    Breast Cancer Res Treat. 2020 Jun 13. pii: 10.1007/s10549-020-05704.
    PubMed     Abstract available


  145. HOLMES DR
    Breast cancer care during a pandemic: an opportune time for cryoablation?
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05724.
    PubMed     Abstract available


  146. RO EJ, Ryu SH, Park EY, Ryu JW, et al
    PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05732.
    PubMed     Abstract available


  147. O'KEEFE TJ, Wallace AM
    Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis.
    Breast Cancer Res Treat. 2020 Jun 11. pii: 10.1007/s10549-020-05733.
    PubMed    


  148. ZHANG J, Lin M, Jin Y, Gu L, et al
    Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05730.
    PubMed     Abstract available


  149. HEEG E, Jensen MB, Mureau MAM, Ejlertsen B, et al
    Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05725.
    PubMed     Abstract available


  150. ALTHOBITI M, Muftah AA, Aleskandarany MA, Joseph C, et al
    The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05719.
    PubMed     Abstract available


  151. TZIKAS AK, Nemes S, Linderholm BK
    A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Breast Cancer Res Treat. 2020 Jun 10. pii: 10.1007/s10549-020-05727.
    PubMed     Abstract available


  152. ALEIXO GFP, Shachar SS, Deal AM, Nyrop KA, et al
    The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2020 Jun 9. pii: 10.1007/s10549-020-05731.
    PubMed     Abstract available


  153. AKHTAR Z, Stearns V, Cartwright P, Blackford AL, et al
    The effect of 1-day multidisciplinary clinic on breast cancer treatment.
    Breast Cancer Res Treat. 2020 Jun 8. pii: 10.1007/s10549-020-05721.
    PubMed     Abstract available


  154. VIDT ME, Potochny J, Dodge D, Green M, et al
    The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05717.
    PubMed     Abstract available


  155. PLYM A, Johansson ALV, Bower H, Wennstig AK, et al
    Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05720.
    PubMed     Abstract available


  156. RAMIREZ-EXPOSITO MJ, Martinez-Martos JM, Duenas-Rodriguez B, Navarro-Cecilia J, et al
    Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins.
    Breast Cancer Res Treat. 2020 Jun 6. pii: 10.1007/s10549-020-05723.
    PubMed     Abstract available


  157. LEON-FERRE RA, Perez EA, Hillman DW, Bueno C, et al
    N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jun 5. pii: 10.1007/s10549-020-05709.
    PubMed     Abstract available


  158. BUONO G, Crispo A, Giuliano M, De Angelis C, et al
    Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
    Breast Cancer Res Treat. 2020 Jun 4. pii: 10.1007/s10549-020-05701.
    PubMed     Abstract available


  159. KRAJNAK S, Schnatz C, Almstedt K, Brenner W, et al
    Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
    Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05711.
    PubMed     Abstract available


  160. TREWIN CB, Johansson ALV, Hjerkind KV, Strand BH, et al
    Stage-specific survival has improved for young breast cancer patients since 2000: but not equally.
    Breast Cancer Res Treat. 2020 Jun 3. pii: 10.1007/s10549-020-05698.
    PubMed     Abstract available


  161. ALTER BP, Best AF
    Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2020 Jun 2. pii: 10.1007/s10549-020-05710.
    PubMed     Abstract available


  162. REINHORN D, Yerushalmi R, Moore A, Desnoyers A, et al
    Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Jun 1. pii: 10.1007/s10549-020-05715.
    PubMed     Abstract available


    May 2020
  163. MIYASHITA H, Cruz C, Malamud S
    Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
    Breast Cancer Res Treat. 2020 May 30. pii: 10.1007/s10549-020-05712.
    PubMed     Abstract available


  164. WU AH, Tseng C, Vigen C, Yu Y, et al
    Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05702.
    PubMed     Abstract available


  165. WARD MC, Vicini F, Al-Hilli Z, Chadha M, et al
    Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05706.
    PubMed     Abstract available


  166. CHO H, Lee S, Sim SH, Park IH, et al
    Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05703.
    PubMed     Abstract available


  167. ONG CT, Ren Y, Thomas SM, Stashko I, et al
    Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis.
    Breast Cancer Res Treat. 2020 May 28. pii: 10.1007/s10549-020-05700.
    PubMed     Abstract available


  168. MUSTONEN L, Vollert J, Rice ASC, Kalso E, et al
    Sensory profiles in women with neuropathic pain after breast cancer surgery.
    Breast Cancer Res Treat. 2020 May 27. pii: 10.1007/s10549-020-05681.
    PubMed     Abstract available


  169. BEITSCH P, Whitworth P, Patel R
    Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID19 pandemic. The COVID19 pandemic breast cancer consortium".
    Breast Cancer Res Treat. 2020 May 26. pii: 10.1007/s10549-020-05694.
    PubMed    


  170. HA SM, Chang JM, Lee SH, Kim ES, et al
    Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05697.
    PubMed     Abstract available


  171. DELGADO-RAMOS GM, Nasir SS, Wang J, Schwartzberg LS, et al
    Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women.
    Breast Cancer Res Treat. 2020 May 23. pii: 10.1007/s10549-020-05684.
    PubMed     Abstract available


  172. JOSEPH C, Alsaleem M, Orah N, Narasimha PL, et al
    Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
    Breast Cancer Res Treat. 2020 May 22. pii: 10.1007/s10549-020-05670.
    PubMed     Abstract available


  173. SCATENA C, Scarpitta R, Innocenti L, Miccoli M, et al
    Androgen receptor expression inversely correlates with histological grade and N stage in ER(+)/PgR(low) male breast cancer.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05682.
    PubMed     Abstract available


  174. MEJDAHL MK, Wohlfahrt J, Holm M, Knoop AS, et al
    Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05689.
    PubMed     Abstract available


  175. DAHN H, Wilke D, Walsh G, Pignol JP, et al
    Radiation and/or endocrine therapy? Recurrence and survival outcomes in women over 70 with early breast cancer after breast-conserving surgery.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05691.
    PubMed     Abstract available


  176. WATANABE J
    Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05695.
    PubMed    


  177. OMILIAN AR, Wei L, Hong CC, Bandera EV, et al
    Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05693.
    PubMed     Abstract available


  178. O'SHAUGHNESSY J
    Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05674.
    PubMed    


  179. LOFTEROD T, Frydenberg H, Flote V, Eggen AE, et al
    Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05679.
    PubMed     Abstract available


  180. DEUTSCH TM, Riethdorf S, Fremd C, Feisst M, et al
    HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05687.
    PubMed     Abstract available


  181. ALMSTEDT K, Mendoza S, Otto M, Battista MJ, et al
    EndoPredict((R)) in early hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05688.
    PubMed     Abstract available


  182. TOMAO F, Verrico M, Tomao S
    Fertility and reproduction in breast cancer patients.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05676.
    PubMed    


  183. ZHONG Y, Xu Y, Zhou Y, Mao F, et al
    Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
    Breast Cancer Res Treat. 2020 May 19. pii: 10.1007/s10549-020-05686.
    PubMed     Abstract available


  184. LI Y, Qin J, Wu J, Dai X, et al
    High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05671.
    PubMed     Abstract available


  185. BACH L, Kostev K, Schiffmann L, Kalder M, et al
    Association between thyroid gland diseases and breast cancer: a case-control study.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05675.
    PubMed     Abstract available


  186. KOUMARIANOU A, Makrantonakis P, Zagouri F, Papadimitriou C, et al
    ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05677.
    PubMed     Abstract available


  187. LEE HB, Han W, Kim SY, Cho N, et al
    Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05678.
    PubMed     Abstract available


  188. HAO Y, Xu B, Yan Q, Zhou M, et al
    Long-term excess body fat in adulthood and the risk of pre- and postmenopausal breast cancer in Chinese women.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05685.
    PubMed     Abstract available


  189. ZHANG LY, Zhang YQ, Zeng YZ, Zhu JL, et al
    TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05673.
    PubMed     Abstract available


  190. SILVA CL, Perestrelo R, Sousa-Ferreira I, Capelinha F, et al
    Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05672.
    PubMed     Abstract available


  191. KALINSKY K, Accordino MK, Hosi K, Hawley JE, et al
    Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
    Breast Cancer Res Treat. 2020 May 14:1-4. doi: 10.1007/s10549-020-05667.
    PubMed    


  192. KALINSKY K, Accordino MK, Hosi K, Hawley JE, et al
    Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City.
    Breast Cancer Res Treat. 2020 May 14. pii: 10.1007/s10549-020-05667.
    PubMed    


  193. ZHOU L, Chen B, Sheng L, Turner A, et al
    The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis.
    Breast Cancer Res Treat. 2020 May 13. pii: 10.1007/s10549-020-05669.
    PubMed     Abstract available


  194. ROJAS KE, Manasseh DM, Rojas M, Mattocks A, et al
    The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer.
    Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05666.
    PubMed     Abstract available


  195. SAITO T, Ono R, Kono S, Asano M, et al
    Physical activity among patients with breast cancer receiving aromatase inhibitors is associated with bone health: a cross-sectional observational study.
    Breast Cancer Res Treat. 2020 May 12. pii: 10.1007/s10549-020-05668.
    PubMed     Abstract available


  196. DU F, Wang W, Wang Y, Li M, et al
    Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05648.
    PubMed     Abstract available


  197. EZRATTY C, Vang S, Brown J, Margolies LR, et al
    Racial/ethnic differences in supplemental imaging for breast cancer screening in women with dense breasts.
    Breast Cancer Res Treat. 2020 May 11. pii: 10.1007/s10549-020-05652.
    PubMed     Abstract available


  198. UMAMAHESWARAN G, Kadambari D, Muthuvel SK, Kalaivani S, et al
    Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Breast Cancer Res Treat. 2020 May 8. pii: 10.1007/s10549-020-05656.
    PubMed     Abstract available


  199. EDMAN KESSLER L, Sigfridsson J, Hatzidaki D, Bergh J, et al
    Chemotherapy use near the end-of-life in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 7. pii: 10.1007/s10549-020-05663.
    PubMed     Abstract available


  200. HEYDON-WHITE A, Suami H, Boyages J, Koelmeyer L, et al
    Assessing breast lymphoedema following breast cancer treatment using indocyanine green lymphography.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05661.
    PubMed     Abstract available


  201. O'TOOLE SA, Spillane C, Huang Y, Fitzgerald MC, et al
    Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05658.
    PubMed     Abstract available


  202. NINO DE GUZMAN E, Song Y, Alonso-Coello P, Canelo-Aybar C, et al
    Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05657.
    PubMed     Abstract available


  203. O'DONNELL PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, et al
    Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    Breast Cancer Res Treat. 2020 May 6. pii: 10.1007/s10549-020-05603.
    PubMed     Abstract available


  204. WANG C, Mu Z, Ye Z, Zhang Z, et al
    Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
    Breast Cancer Res Treat. 2020 May 4. pii: 10.1007/s10549-020-05662.
    PubMed     Abstract available


  205. WANG RX, Ji P, Gong Y, Shao ZM, et al
    Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
    Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05660.
    PubMed     Abstract available


  206. STOVGAARD ES, Bokharaey M, List-Jensen K, Roslind A, et al
    PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
    Breast Cancer Res Treat. 2020 May 2. pii: 10.1007/s10549-020-05655.
    PubMed     Abstract available


    April 2020
  207. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos-Calderon C, Perez-Gomez B, et al
    Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study.
    Breast Cancer Res Treat. 2020 Apr 30. pii: 10.1007/s10549-020-05600.
    PubMed     Abstract available


  208. SOARES LR, Rosa VDL, Freitas-Junior R
    Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life.
    Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05659.
    PubMed    


  209. ALJOHANI AI, Joseph C, Kurozumi S, Mohammed OJ, et al
    Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Apr 29. pii: 10.1007/s10549-020-05646.
    PubMed     Abstract available


  210. TROGDON JG, Baggett CD, Gogate A, Reeder-Hayes KE, et al
    Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
    Breast Cancer Res Treat. 2020 Apr 28. pii: 10.1007/s10549-020-05654.
    PubMed     Abstract available


  211. HUNT BG, Wicker CA, Bourn JR, Lower EE, et al
    MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05653.
    PubMed     Abstract available


  212. ALTUNDAG K
    Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?
    Breast Cancer Res Treat. 2020 Apr 27. pii: 10.1007/s10549-020-05649.
    PubMed    


  213. DIETZ JR, Moran MS, Isakoff SJ, Kurtzman SH, et al
    Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium.
    Breast Cancer Res Treat. 2020 Apr 24. pii: 10.1007/s10549-020-05644.
    PubMed     Abstract available


  214. YOO TK, Kang BJ, Kim SH, Song BJ, et al
    Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
    Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05636.
    PubMed     Abstract available


  215. GOTTSCHAU M, Kjaer SK, Settnes A, Aalborg GL, et al
    Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study.
    Breast Cancer Res Treat. 2020 Apr 23. pii: 10.1007/s10549-020-05628.
    PubMed     Abstract available


  216. BROWN TA 2ND, Mittendorf EA, Hale DF, Myers JW 3rd, et al
    Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Breast Cancer Res Treat. 2020 Apr 22. pii: 10.1007/s10549-020-05638.
    PubMed     Abstract available


  217. JACENE HA, DiPiro PJ, Bellon J, Hu J, et al
    Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05631.
    PubMed     Abstract available


  218. MIYASHITA H, Satoi S, Kuno T, Cruz C, et al
    Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05640.
    PubMed     Abstract available


  219. ZENG C, Guo X, Wen W, Shi J, et al
    Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05643.
    PubMed     Abstract available


  220. MALOUFF TD, Mahajan A, Mutter RW, Krishnan S, et al
    Carbon ion radiation therapy in breast cancer: a new frontier.
    Breast Cancer Res Treat. 2020 Apr 21. pii: 10.1007/s10549-020-05641.
    PubMed     Abstract available


  221. KAWACHI A, Yamashita S, Okochi-Takada E, Hirakawa A, et al
    BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05647.
    PubMed     Abstract available


  222. KWAK A, Jacobs J, Haggett D, Jimenez R, et al
    Evaluation and management of insomnia in women with breast cancer.
    Breast Cancer Res Treat. 2020 Apr 20. pii: 10.1007/s10549-020-05635.
    PubMed     Abstract available


  223. JING J, Feng R, Zhang X, Li M, et al
    Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China.
    Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05632.
    PubMed     Abstract available


  224. HERSHMAN DL, Till C, Wright JD, Accordino M, et al
    Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials.
    Breast Cancer Res Treat. 2020 Apr 18. pii: 10.1007/s10549-020-05634.
    PubMed     Abstract available


  225. HAAS CB, Nekhlyudov L, Lee JM, Javid SH, et al
    Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2020 Apr 17. pii: 10.1007/s10549-020-05637.
    PubMed     Abstract available


  226. JORGENSEN CLT, Forsare C, Bendahl PO, Falck AK, et al
    Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
    Breast Cancer Res Treat. 2020 Apr 16. pii: 10.1007/s10549-020-05627.
    PubMed     Abstract available


  227. ASAOKA M, Patnaik SK, Zhang F, Ishikawa T, et al
    Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response.
    Breast Cancer Res Treat. 2020 Apr 13. pii: 10.1007/s10549-020-05630.
    PubMed     Abstract available


  228. GIARDIELLO D, Hauptmann M, Steyerberg EW, Adank MA, et al
    Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts.
    Breast Cancer Res Treat. 2020 Apr 11. pii: 10.1007/s10549-020-05611.
    PubMed     Abstract available


  229. LAWS MJ, Ziegler Y, Shahoei SH, Dey P, et al
    Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
    Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05629.
    PubMed     Abstract available


  230. GREENWELL K, Hussain L, Lee D, Bramlage M, et al
    Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
    Breast Cancer Res Treat. 2020 Apr 10. pii: 10.1007/s10549-020-05599.
    PubMed     Abstract available


  231. DRULLINSKY PR, Hurvitz SA
    Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
    Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05618.
    PubMed     Abstract available


  232. RIBI K, Luo W, Walley BA, Burstein HJ, et al
    Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
    Breast Cancer Res Treat. 2020 Apr 9. pii: 10.1007/s10549-020-05622.
    PubMed     Abstract available


  233. HIRAKATA T, Fujii T, Kurozumi S, Katayama A, et al
    FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05619.
    PubMed     Abstract available


  234. PINERO-MADRONA A, Ripoll-Orts F, Sanchez-Mendez JI, Chaves-Benito A, et al
    External validation of a prognostic model based on total tumor load of sentinel lymph node for early breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05623.
    PubMed     Abstract available


  235. ALEIXO GFP, Deal AM, Nyrop KA, Muss HB, et al
    Association of body composition with function in women with early breast cancer.
    Breast Cancer Res Treat. 2020 Apr 6. pii: 10.1007/s10549-020-05624.
    PubMed     Abstract available


  236. WATANABE J, Saito M, Horimoto Y, Nakamoto S, et al
    A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
    Breast Cancer Res Treat. 2020 Apr 5. pii: 10.1007/s10549-020-05626.
    PubMed     Abstract available


  237. HIRAI T, Nemoto A, Ito Y, Matsuura M, et al
    Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05615.
    PubMed     Abstract available


  238. LE AN, Harton J, Desai H, Powers J, et al
    Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05612.
    PubMed     Abstract available


  239. FRANZOI MA, Vandeputte C, Eiger D, Caparica R, et al
    Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
    Breast Cancer Res Treat. 2020 Apr 3. pii: 10.1007/s10549-020-05617.
    PubMed     Abstract available


  240. PAN L, Chen X, Fu S, Yu W, et al
    LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05613.
    PubMed     Abstract available


  241. SUNDELIN EIO, Al-Suliman N, Vahl P, Vendelbo M, et al
    Metformin is distributed to tumor tissue in breast cancer patients in vivo: A (11)C-metformin PET/CT study.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05621.
    PubMed     Abstract available


  242. DENYS H, Martinez-Mena CL, Martens MT, D'Hondt RG, et al
    Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05604.
    PubMed     Abstract available


  243. LEI YY, Ho SC, Cheng A, Kwok C, et al
    The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 1. pii: 10.1007/s10549-020-05616.
    PubMed     Abstract available


  244. NEVEN P, Froyman W, Timmerman S, Timmerman D, et al
    Uterine ultrasound and endometrial biopsy in tamoxifen users.
    Breast Cancer Res Treat. 2020;180:833-834.
    PubMed    


  245. ALTUNDAG K
    HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology.
    Breast Cancer Res Treat. 2020;180:829.
    PubMed    


    March 2020
  246. GONG IY, Yan AT, Earle CC, Trudeau ME, et al
    Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05614.
    PubMed     Abstract available


  247. VRIENS IJH, Ter Welle-Butalid EM, de Boer M, de Die-Smulders CEM, et al
    Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05598.
    PubMed     Abstract available


  248. BHATTACHARJEE A, Rajendra J, Dikshit R, Dutt S, et al
    HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05608.
    PubMed     Abstract available


  249. BRANDBERG Y, Johansson H, Hellstrom M, Gnant M, et al
    Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05602.
    PubMed     Abstract available


  250. JOBSEN JJ, Struikmans H, van der Palen J, Siemerink E, et al
    The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer.
    Breast Cancer Res Treat. 2020 Mar 30. pii: 10.1007/s10549-020-05610.
    PubMed     Abstract available


  251. EL ANSARI R, Alfarsi L, Craze ML, Masisi BK, et al
    The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05586.
    PubMed     Abstract available


  252. GENNARI A, Foca F, Zamarchi R, Rocca A, et al
    Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05596.
    PubMed     Abstract available


  253. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2020 Mar 19. pii: 10.1007/s10549-020-05597.
    PubMed     Abstract available


  254. PANZIRONI G, Moffa G, Galati F, Marzocca F, et al
    Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05592.
    PubMed     Abstract available


  255. HASSETT MJ, Li H, Burstein HJ, Punglia RS, et al
    Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05587.
    PubMed     Abstract available


  256. SIMONS JM, Koppert LB, Luiten EJT, van der Pol CC, et al
    De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05589.
    PubMed     Abstract available


  257. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Correction to: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05594.
    PubMed     Abstract available


  258. MA G, Zhang B, Xu J
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05593.
    PubMed    


  259. YUAN C, Xie Z, Bian J, Huo J, et al
    Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05591.
    PubMed     Abstract available


  260. CROLLEY VE, Marashi H, Rawther S, Sirohi B, et al
    The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05578.
    PubMed     Abstract available


  261. ISHIGURO H, Masuda N, Sato N, Higaki K, et al
    A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05590.
    PubMed     Abstract available


  262. O'SULLIVAN CC, Irshad S, Wang Z, Tang Z, et al
    Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
    Breast Cancer Res Treat. 2020 Mar 11. pii: 10.1007/s10549-020-05585.
    PubMed     Abstract available


  263. IWASE M, Ando M, Aogi K, Aruga T, et al
    Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Mar 5. pii: 10.1007/s10549-020-05580.
    PubMed     Abstract available


  264. ANDREANO KJ, Wardell SE, Baker JG, Desautels TK, et al
    G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 4. pii: 10.1007/s10549-020-05575.
    PubMed     Abstract available


  265. TAYLOR LJ, Steiman JS, Anderson B, Schumacher JR, et al
    Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?
    Breast Cancer Res Treat. 2020 Mar 3. pii: 10.1007/s10549-020-05579.
    PubMed     Abstract available


  266. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05567.
    PubMed     Abstract available


  267. MASUDA T, Fujimoto H, Teranaka R, Kuroda M, et al
    Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05581.
    PubMed     Abstract available


    February 2020
  268. JEON YW, Bang HW, Suh YJ, Kim G, et al
    The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy.
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05568.
    PubMed     Abstract available


  269. PARACHA N, Reyes A, Dieras V, Krop I, et al
    Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analys
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05577.
    PubMed     Abstract available


  270. ROJAS-LIMA E, Gamboa-Loira B, Cebrian ME, Rothenberg SJ, et al
    A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
    Breast Cancer Res Treat. 2020 Feb 22. pii: 10.1007/s10549-020-05562.
    PubMed     Abstract available


  271. LAMBERT-COTE L, Bouhnik AD, Bendiane MK, Berenger C, et al
    Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Breast Cancer Res Treat. 2020 Feb 21. pii: 10.1007/s10549-020-05549.
    PubMed     Abstract available


  272. PAN K, Ray RM, Cauley JA, Shadyab AH, et al
    Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05576.
    PubMed     Abstract available


  273. KIM M, Kim H, Ahn SH, Tabatabaie V, et al
    Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05566.
    PubMed     Abstract available


  274. CHEN L, Fu F, Huang M, Lv J, et al
    The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Breast Cancer Res Treat. 2020 Feb 18. pii: 10.1007/s10549-020-05573.
    PubMed     Abstract available


  275. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Feb 17. pii: 10.1007/s10549-020-05564.
    PubMed     Abstract available


  276. YUNG R, Ray RM, Roth J, Johnson L, et al
    The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Feb 15. pii: 10.1007/s10549-020-05572.
    PubMed     Abstract available


  277. CORONA SP, Bortul M, Scomersi S, Bigal C, et al
    Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05565.
    PubMed     Abstract available


  278. ZHANG L, Hsieh MC, Petkov V, Yu Q, et al
    Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05557.
    PubMed     Abstract available


  279. CHEN Z, Xu L, Shi W, Zeng F, et al
    Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017.
    Breast Cancer Res Treat. 2020 Feb 13. pii: 10.1007/s10549-020-05561.
    PubMed     Abstract available


  280. RYPENS C, Marsan M, Van Berckelaer C, Billiet C, et al
    Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05571.
    PubMed     Abstract available


  281. RACHNER TD, Gobel A, Hoffmann O, Erdmann K, et al
    High serum levels of periostin are associated with a poor survival in breast cancer.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05570.
    PubMed     Abstract available


  282. SARMIENTO S, McColl M, Musavi L, Gani F, et al
    Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05556.
    PubMed     Abstract available


  283. SORSCHER S, Ansley K, Delaney SD, Ramkissoon S, et al
    The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05569.
    PubMed     Abstract available


  284. SUN X, Wang XE, Zhang ZP, Shi ZQ, et al
    Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05559.
    PubMed     Abstract available


  285. YU M, Chen Y, Wang Z, Ding X, et al
    pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05560.
    PubMed     Abstract available


  286. MILLS MN, Figura NB, Arrington JA, Yu HM, et al
    Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05552.
    PubMed     Abstract available


  287. GUO S, Zhang C, Mottamal M, Hossain A, et al
    GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05558.
    PubMed     Abstract available


  288. JOOB B, Wiwanitkit V
    CYP24A1 polymorphisms and breast cancer risk.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05553.
    PubMed    



  289. UK Interdisciplinary Breast Cancer Symposium 2020.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-019-05514.
    PubMed    


  290. PAREKH VS, Jacobs MA
    Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05533.
    PubMed     Abstract available


  291. KIM HS, Yoo TK, Park WC, Chae BJ, et al
    The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05550.
    PubMed     Abstract available


  292. ZHU J, Wang F, Shi L, Cai H, et al
    Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05541.
    PubMed     Abstract available


  293. SHIBAYAMA T, Low SK, Ono M, Kobayashi T, et al
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-019-05512.
    PubMed     Abstract available


  294. DICORPO D, Tiwari A, Tang R, Griffin M, et al
    The role of Micro-CT in imaging breast cancer specimens.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05547.
    PubMed     Abstract available


  295. LI M, Xiong Y, Liao C, He Y, et al
    Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2020 Feb 1. pii: 10.1007/s10549-020-05551.
    PubMed     Abstract available


  296. ZDRAVKOVIC D, Granic M, Crnokrak B
    Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?
    Breast Cancer Res Treat. 2020;179:765.
    PubMed    


  297. ALTUNDAG K
    Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
    Breast Cancer Res Treat. 2020;179:763.
    PubMed    


  298. TRACEY N, Creedon H, Kemp AJ, Culley J, et al
    HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Breast Cancer Res Treat. 2020;179:543-555.
    PubMed     Abstract available


    January 2020
  299. LINNENBRINGER E, Geronimus AT, Davis KL, Bound J, et al
    Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
    Breast Cancer Res Treat. 2020 Jan 30. pii: 10.1007/s10549-020-05545.
    PubMed     Abstract available


  300. QIAN XL, Xu P, Zhang YQ, Song YM, et al
    Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 29. pii: 10.1007/s10549-020-05540.
    PubMed     Abstract available


  301. RAINVILLE I, Hatcher S, Rosenthal E, Larson K, et al
    High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Breast Cancer Res Treat. 2020 Jan 28. pii: 10.1007/s10549-020-05543.
    PubMed     Abstract available


  302. ROSE M, Svensson H, Handler J, Hoyer U, et al
    Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05544.
    PubMed     Abstract available


  303. DE BONIFACE J, Ahlgren J, Andersson Y, Bergkvist L, et al
    The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05537.
    PubMed     Abstract available


  304. KANAI A, McNamara KM, Iwabuchi E, Miki Y, et al
    Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05523.
    PubMed     Abstract available


  305. MOUSLIM MC, Johnson RM, Dean LT
    Healthcare system distrust and the breast cancer continuum of care.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05538.
    PubMed     Abstract available


  306. ZENG F, Heng J, Guo X, Wang Y, et al
    The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05536.
    PubMed     Abstract available


  307. PLICHTA JK, Thomas SM, Vernon R, Fayanju OM, et al
    Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05542.
    PubMed     Abstract available


  308. FERRARIS C, Ballestra B, Listorti C, Cappelletti V, et al
    Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05534.
    PubMed     Abstract available


  309. LEE C, Check DK, Manace Brenman L, Kushi LH, et al
    Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Breast Cancer Res Treat. 2020 Jan 23. pii: 10.1007/s10549-020-05539.
    PubMed     Abstract available


  310. LI J, Fu F, Yu L, Huang M, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05528.
    PubMed     Abstract available


  311. BANSOD S, Desai R
    Nationwide prevalence and trends of acute cardiovascular and cerebrovascular events among adult breast cancer survivors with a history of radiation therapy.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05535.
    PubMed    


  312. FAYANJU OM, Ren Y, Greenup RA, Plichta JK, et al
    Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
    Breast Cancer Res Treat. 2020 Jan 20. pii: 10.1007/s10549-020-05529.
    PubMed     Abstract available


  313. HULSBERGEN AFC, Cho LD, Mammi M, Lamba N, et al
    Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05531.
    PubMed     Abstract available


  314. MASUDA N, Ohtani S, Takano T, Inoue K, et al
    A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05524.
    PubMed     Abstract available


  315. KLAESTAD E, Opdahl S, Engstrom MJ, Ytterhus B, et al
    MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05532.
    PubMed     Abstract available


  316. YE ZJ, Zhang Z, Zhang XY, Tang Y, et al
    Effectiveness of adjuvant supportive-expressive group therapy for breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05526.
    PubMed     Abstract available


  317. GARCIA X, Elia A, Galizzi L, May M, et al
    Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05527.
    PubMed     Abstract available


  318. LOPEZ G, Fusco N
    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05530.
    PubMed    


  319. ROTILI A, Trimboli RM, Penco S, Pesapane F, et al
    Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05519.
    PubMed     Abstract available


  320. BJERKESET E, Rohrl K, Schou-Bredal I
    Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-020-05522.
    PubMed     Abstract available


  321. TADROS AB, Moo TA, Stempel M, Zabor EC, et al
    Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05520.
    PubMed     Abstract available


  322. YAO S, Laurent CA, Roh JM, Lo J, et al
    Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
    Breast Cancer Res Treat. 2020 Jan 7. pii: 10.1007/s10549-019-05518.
    PubMed     Abstract available


  323. WIJAYABAHU AT, Egan KM, Yaghjyan L
    Uterine cancer in breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05516.
    PubMed     Abstract available


  324. KIM SS, Lee MH, Lee MO
    Histone methyltransferases regulate the transcriptional expression of ERalpha and the proliferation of tamoxifen-resistant breast cancer cells.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05517.
    PubMed     Abstract available


  325. TYNAN M, Peshkin BN, Isaacs C, Willey S, et al
    Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2020 Jan 1. pii: 10.1007/s10549-019-05515.
    PubMed     Abstract available


  326. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Authors' reply to the comment "Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism".
    Breast Cancer Res Treat. 2020;179:519-520.
    PubMed    


  327. GRADISHAR B
    Editorial.
    Breast Cancer Res Treat. 2020;179:1.
    PubMed    


  328. DE AZAMBUJA E, Ponde N, Procter M, Rastogi P, et al
    A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
    Breast Cancer Res Treat. 2020;179:161-171.
    PubMed     Abstract available


  329. HAWSE JR, Carter JM, Aspros KGM, Bruinsma ES, et al
    Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.
    Breast Cancer Res Treat. 2020;179:241-249.
    PubMed     Abstract available


    December 2019
  330. LI Y, Zhou Y, Mao F, Lin Y, et al
    Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Breast Cancer Res Treat. 2019 Dec 21. pii: 10.1007/s10549-019-05513.
    PubMed     Abstract available


  331. CHEN HL, Du L, Li XM
    Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 19. pii: 10.1007/s10549-019-05510.
    PubMed    


  332. HEUBLEIN S, Egger M, Zhu J, Berger L, et al
    Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 11. pii: 10.1007/s10549-019-05503.
    PubMed     Abstract available


  333. KIM MH, Kim GM, Kim JH, Kim JY, et al
    Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Breast Cancer Res Treat. 2019 Dec 6. pii: 10.1007/s10549-019-05505.
    PubMed     Abstract available


  334. YASRI S, Wiwanitkit V
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism.
    Breast Cancer Res Treat. 2019;178:713.
    PubMed    


    November 2019
  335. HII LW, Chung FF, Soo JS, Tan BS, et al
    Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
    Breast Cancer Res Treat. 2019 Nov 29. pii: 10.1007/s10549-019-05504.
    PubMed     Abstract available


  336. CLAESSENS AKM, Timman R, Busschbach JJ, Bouma JM, et al
    The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
    Breast Cancer Res Treat. 2019 Nov 28. pii: 10.1007/s10549-019-05495.
    PubMed     Abstract available


  337. ANDERSEN JLM, Hansen L, Thomsen BLR, Christiansen LR, et al
    Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.
    Breast Cancer Res Treat. 2019 Nov 26. pii: 10.1007/s10549-019-05497.
    PubMed     Abstract available


  338. WU Y, Ouyang T, Li J, Wang T, et al
    Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Nov 25. pii: 10.1007/s10549-019-05483.
    PubMed     Abstract available


  339. KULIGINA ES, Sokolenko AP, Bizin IV, Romanko AA, et al
    Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39.
    Breast Cancer Res Treat. 2019 Nov 21. pii: 10.1007/s10549-019-05492.
    PubMed     Abstract available


  340. ALMEIDA M, Soares M, Ramalhinho AC, Moutinho JF, et al
    The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
    Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05494.
    PubMed     Abstract available


  341. FERNANDEZ AI, Geng X, Chaldekas K, Harris B, et al
    The orphan nuclear receptor estrogen-related receptor beta (ERRbeta) in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05485.
    PubMed     Abstract available


  342. ROSENBERGER LH, Ren Y, Thomas SM, Greenup RA, et al
    Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
    Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05500.
    PubMed     Abstract available


  343. FRISELL A, Lagergren J, Halle M, de Boniface J, et al
    Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information.
    Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05496.
    PubMed     Abstract available


  344. NYROP KA, Deal AM, Shachar SS, Park J, et al
    Weight trajectories in women receiving systemic adjuvant therapy for breast cancer.
    Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05501.
    PubMed     Abstract available


  345. WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
    Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
    Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05498.
    PubMed     Abstract available


  346. DREWS-ELGER K, Sandoval-Leon AC, Ergonul AB, Jegg AM, et al
    Paget's disease of the nipple in a Her2-positive breast cancer xenograft model.
    Breast Cancer Res Treat. 2019 Nov 13. pii: 10.1007/s10549-019-05490.
    PubMed     Abstract available


  347. TIAINEN S, Masarwah A, Oikari S, Rilla K, et al
    Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis.
    Breast Cancer Res Treat. 2019 Nov 12. pii: 10.1007/s10549-019-05491.
    PubMed     Abstract available


  348. KANSTRUP C, Teilum D, Rejnmark L, Bigaard JV, et al
    25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival.
    Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05486.
    PubMed     Abstract available


  349. KUROZUMI S, Alsaeed S, Orah N, Miligy IM, et al
    Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
    Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05488.
    PubMed     Abstract available


  350. CAO S, Wei F, Zhou J, Zhu Z, et al
    The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2019 Nov 6. pii: 10.1007/s10549-019-05484.
    PubMed     Abstract available


  351. KARIRI YA, Joseph C, Kurozumi S, Toss MS, et al
    Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Breast Cancer Res Treat. 2019 Nov 2. pii: 10.1007/s10549-019-05466.
    PubMed     Abstract available


  352. STRIZOVA Z, Vachtenheim J Jr, Bartunkova J
    The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression.
    Breast Cancer Res Treat. 2019;178:247-248.
    PubMed    


  353. TRIMBOLI RM, Schiaffino S, Sardanelli F
    In BRCA mutation carriers breast conserving surgery may not be the best choice.
    Breast Cancer Res Treat. 2019;178:245-246.
    PubMed    


    October 2019
  354. SHIM EJ, Lee JW, Cho J, Jung HK, et al
    Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.
    Breast Cancer Res Treat. 2019 Oct 31. pii: 10.1007/s10549-019-05479.
    PubMed     Abstract available


  355. SRIDHAR S, Rajesh C, Jishnu PV, Jayaram P, et al
    Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Oct 29. pii: 10.1007/s10549-019-05477.
    PubMed     Abstract available


  356. ZHENG L, Li X, Gu Y, Lv X, et al
    Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
    Breast Cancer Res Treat. 2019 Oct 26. pii: 10.1007/s10549-019-05478.
    PubMed     Abstract available


  357. BATENBURG MCT, Gregorowitsch ML, Maarse W, Witkamp A, et al
    Patient-reported cosmetic satisfaction and the long-term association with quality of life in irradiated breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05470.
    PubMed     Abstract available


  358. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05480.
    PubMed     Abstract available


  359. BEDNAREK R, Selmi A, Wojkowska D, Karolczak K, et al
    Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05471.
    PubMed     Abstract available


  360. BANYS-PALUCHOWSKI M, Milde-Langosch K, Fehm T, Witzel I, et al
    Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05474.
    PubMed     Abstract available


  361. KOMOROWSKI AS, Pezo RC
    Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05472.
    PubMed     Abstract available


  362. LEE YJ, Park H, Kang CM, Gwark SC, et al
    Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05469.
    PubMed     Abstract available


  363. NAIK H, Leung B, Laskin J, McDonald M, et al
    Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults.
    Breast Cancer Res Treat. 2019 Oct 19. pii: 10.1007/s10549-019-05468.
    PubMed     Abstract available


  364. JEONG SH, An Y, Ahn C, Park B, et al
    Body mass index and risk of breast cancer molecular subtypes in Korean women: a case-control study.
    Breast Cancer Res Treat. 2019 Oct 18. pii: 10.1007/s10549-019-05451.
    PubMed     Abstract available


  365. IWASE T, Sangai T, Fujimoto H, Sawabe Y, et al
    Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05467.
    PubMed     Abstract available


  366. CARENE D, Tran-Dien A, Lemonnier J, Dalenc F, et al
    Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05462.
    PubMed     Abstract available


  367. HERRSCHER H, Velten M, Leblanc J, Kalish-Weindling M, et al
    Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 14. pii: 10.1007/s10549-019-05439.
    PubMed     Abstract available


  368. RODRIGUES-FERREIRA S, Molina A, Nahmias C
    Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer.
    Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05463.
    PubMed     Abstract available


  369. QIAN X, Li Z, Ruan G, Tu C, et al
    Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05464.
    PubMed     Abstract available


  370. AMMITZBOLL G, Andersen KG, Bidstrup PE, Johansen C, et al
    Effect of progressive resistance training on persistent pain after axillary dissection in breast cancer: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Oct 11. pii: 10.1007/s10549-019-05461.
    PubMed     Abstract available


  371. SHI Z, Rundle A, Genkinger JM, Cheung YK, et al
    Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study.
    Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05457.
    PubMed     Abstract available


  372. ALJOHANI AI, Toss MS, Kurozumi S, Joseph C, et al
    The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
    Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05459.
    PubMed     Abstract available


  373. GONZALEZ-RODRIGUEZ E, Aubry-Rozier B, Stoll D, Zaman K, et al
    Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
    Breast Cancer Res Treat. 2019 Oct 9. pii: 10.1007/s10549-019-05458.
    PubMed     Abstract available


  374. HWANG KT, Kim J, Jung J, Kim BH, et al
    Long-term prognostic effect of hormone receptor subtype on breast cancer.
    Breast Cancer Res Treat. 2019 Oct 8. pii: 10.1007/s10549-019-05456.
    PubMed     Abstract available


  375. BLANCHETTE PS, Lam M, Richard L, Allen B, et al
    Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Breast Cancer Res Treat. 2019 Oct 1. pii: 10.1007/s10549-019-05430.
    PubMed     Abstract available


    September 2019
  376. WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
    Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
    Breast Cancer Res Treat. 2019 Sep 27. pii: 10.1007/s10549-019-05454.
    PubMed     Abstract available


  377. SAMUEL CA, Spencer JC, Rosenstein DL, Reeder-Hayes KE, et al
    Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Sep 25. pii: 10.1007/s10549-019-05449.
    PubMed     Abstract available


  378. PU M, Messer K, Davies SR, Vickery TL, et al
    Research-based PAM50 signature and long-term breast cancer survival.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05446.
    PubMed     Abstract available


  379. YEN TWF, Laud PW, McGinley EL, Pezzin LE, et al
    Prevalence and scope of advanced practice provider oncology care among Medicare beneficiaries with breast cancer.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05447.
    PubMed     Abstract available


  380. WOLFS JAGN, de Joode LGEH, van der Hulst RRWJ, Qiu SS, et al
    Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05450.
    PubMed     Abstract available


  381. JEON J, Kim SE, Lee DY, Choi D, et al
    Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
    Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05448.
    PubMed     Abstract available


  382. LEONE JP, Duda DG, Hu J, Barry WT, et al
    A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05445.
    PubMed     Abstract available


  383. SYNNOTT NC, O'Connell D, Crown J, Duffy MJ, et al
    COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2019 Sep 19. pii: 10.1007/s10549-019-05435.
    PubMed     Abstract available


  384. TERADA M, Yoshimura A, Sawaki M, Hattori M, et al
    Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05443.
    PubMed     Abstract available


  385. ALLOTT EH, Shan Y, Chen M, Sun X, et al
    Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05442.
    PubMed     Abstract available


  386. VANGANGELT KMH, Kramer CJH, Bastiaannet E, Putter H, et al
    The intra-tumoural stroma in patients with breast cancer increases with age.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05422.
    PubMed     Abstract available


  387. BATTISTI NML, True V, Chaabouni N, Chopra N, et al
    Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05444.
    PubMed     Abstract available


  388. GORBOUNOV M, Carleton NM, Asch-Kendrick RJ, Xian L, et al
    High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 Sep 17. pii: 10.1007/s10549-019-05419.
    PubMed     Abstract available


  389. PINARD C, Debled M, Ben Rejeb H, Velasco V, et al
    Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Sep 16. pii: 10.1007/s10549-019-05437.
    PubMed     Abstract available


  390. CHENG AS, Leung SCY, Gao D, Burugu S, et al
    Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2019 Sep 14. pii: 10.1007/s10549-019-05438.
    PubMed     Abstract available


  391. BRINKHAUS B, Kirschbaum B, Stockigt B, Binting S, et al
    Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study.
    Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05431.
    PubMed     Abstract available


  392. DU T, Liu B, Wang Z, Wan X, et al
    CpG methylation signature predicts prognosis in breast cancer.
    Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05417.
    PubMed     Abstract available


  393. DE LIGT KM, Heins M, Verloop J, Ezendam NPM, et al
    The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05433.
    PubMed     Abstract available


  394. SCARPITTA R, Zanna I, Aretini P, Gambino G, et al
    Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.
    Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05429.
    PubMed     Abstract available


  395. COUGHLIN SS, Caplan LS, Williams V
    Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05424.
    PubMed     Abstract available


  396. STEENBRUGGEN TG, Bouwer NI, Smorenburg CH, Rier HN, et al
    Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05427.
    PubMed     Abstract available


  397. JEON YW, You SH, Lee JE, Youn HJ, et al
    Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05426.
    PubMed     Abstract available


  398. KACZMAREK E, Saint-Martin C, Pierga JY, Brain E, et al
    Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
    Breast Cancer Res Treat. 2019 Sep 5. pii: 10.1007/s10549-019-05423.
    PubMed     Abstract available


  399. LAGACE F, Ghazawi FM, Le M, Rahme E, et al
    Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada.
    Breast Cancer Res Treat. 2019 Sep 4. pii: 10.1007/s10549-019-05418.
    PubMed     Abstract available


  400. RIEDEL F, Heil J, Feisst M, Rezai M, et al
    Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Breast Cancer Res Treat. 2019;177:457-467.
    PubMed     Abstract available


  401. NIRAVATH P, Hilsenbeck SG, Wang T, Jiralerspong S, et al
    Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
    Breast Cancer Res Treat. 2019;177:427-435.
    PubMed     Abstract available


  402. BLACKWOOD J, Wright FC, Hong NJL, Gagliardi AR, et al
    Quality of DCIS information on the internet: a content analysis.
    Breast Cancer Res Treat. 2019;177:295-305.
    PubMed     Abstract available


  403. YU Q, Huang K, Zhu Y, Chen X, et al
    Preliminary results of computer-aided diagnosis for magnetic resonance imaging of solid breast lesions.
    Breast Cancer Res Treat. 2019;177:419-426.
    PubMed     Abstract available


  404. YANG Y, Li S, Liu G, Shao Z, et al
    Is core needle biopsy effective at diagnosing male breast lesions?
    Breast Cancer Res Treat. 2019;177:507-511.
    PubMed     Abstract available


    August 2019
  405. LI C, Fan H, Xiang Q, Xu L, et al
    Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05421.
    PubMed     Abstract available


  406. HOVELING LA, van Maaren MC, Hueting T, Strobbe LJA, et al
    Validation of the online prediction model CancerMath in the Dutch breast cancer population.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05399.
    PubMed     Abstract available


  407. ALFARSI LH, Ansari RE, Craze ML, Toss MS, et al
    CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05420.
    PubMed     Abstract available


  408. KLUZNIAK W, Wokolorczyk D, Rusak B, Huzarski T, et al
    Inherited variants in XRCC2 and the risk of breast cancer.
    Breast Cancer Res Treat. 2019 Aug 28. pii: 10.1007/s10549-019-05415.
    PubMed     Abstract available


  409. ZHI WI, Chen P, Kwon A, Chen C, et al
    Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05416.
    PubMed     Abstract available


  410. CHEN J, Douglass J, Prasath V, Neace M, et al
    The microbiome and breast cancer: a review.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05407.
    PubMed     Abstract available


  411. KUBO M, Kawai M, Kumamaru H, Miyata H, et al
    A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05413.
    PubMed     Abstract available


  412. VERBEEK JGE, Atema V, Mewes JC, van Leeuwen M, et al
    Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05410.
    PubMed     Abstract available


  413. DE BOER AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, et al
    Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05412.
    PubMed     Abstract available


  414. D'AMBROSIO V, Vena F, Di Mascio D, Faralli I, et al
    Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05408.
    PubMed     Abstract available


  415. CERRETINI R, Mercado G, Morganstein J, Schiaffi J, et al
    Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Breast Cancer Res Treat. 2019 Aug 24. pii: 10.1007/s10549-019-05411.
    PubMed     Abstract available


  416. LUNDGREN C, Bendahl PO, Borg A, Ehinger A, et al
    Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05378.
    PubMed     Abstract available


  417. SIDDAPPA CM, Pillai SG, Snider J, Alldredge P, et al
    Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05405.
    PubMed     Abstract available


  418. BATTISTI NML, Tong D, Ring A, Smith I, et al
    Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05406.
    PubMed     Abstract available


  419. WANG X, Kong X, Fang Y, Wang J, et al
    Letter regarding Sopik V et al. entitled "Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ".
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05389.
    PubMed    


  420. ROCCA A, Melegari E, Palleschi M
    Precision medicine: PI3K targeting in advanced breast cancer.
    Breast Cancer Res Treat. 2019 Aug 19. pii: 10.1007/s10549-019-05409.
    PubMed    


  421. VIALE G, Hanlon Newell AE, Walker E, Harlow G, et al
    Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes.
    Breast Cancer Res Treat. 2019 Aug 17. pii: 10.1007/s10549-019-05402.
    PubMed     Abstract available


  422. EAGLEHOUSE YL, Georg MW, Shriver CD, Zhu K, et al
    Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05404.
    PubMed     Abstract available


  423. BARRETO-COELHO P, Cerbon D, Schlumbrecht M, Parra CM, et al
    Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05403.
    PubMed     Abstract available


  424. LIU YL, Wang DW, Yang ZC, Ma R, et al
    Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05385.
    PubMed     Abstract available


  425. LAI CPT, Yeong JPS, Tan AS, Ong CHC, et al
    Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.
    Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05396.
    PubMed     Abstract available


  426. RUSAK B, Kluzniak W, Wokolorczyk D, Stempa K, et al
    Allelic modification of breast cancer risk in women with an NBN mutation.
    Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05391.
    PubMed     Abstract available


  427. KIM JY, Lee E, Park K, Im SA, et al
    Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
    Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05400.
    PubMed     Abstract available


  428. HIDA AI, Watanabe T, Sagara Y, Kashiwaba M, et al
    Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05390.
    PubMed     Abstract available


  429. TANG E, Rowland A, McKinnon RA, Sorich MJ, et al
    Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05393.
    PubMed     Abstract available


  430. ARNAOUT A, Robertson S, Pond GR, Vieth R, et al
    Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05392.
    PubMed     Abstract available


  431. ROBINSON A, Stober C, Fergusson D, Kehoe A, et al
    A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05388.
    PubMed     Abstract available


  432. ARNAOUT A, Robertson SJ, Pond GR, Lee H, et al
    A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05381.
    PubMed     Abstract available


  433. LIU ZB, Ezzedine NE, Eterovic AK, Ensor JE, et al
    Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05374.
    PubMed     Abstract available


  434. HE J, McLaughlin RP, van der Noord V, Foekens JA, et al
    Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05380.
    PubMed     Abstract available


  435. LIU Y, Wu S, Shi X, Luo Y, et al
    HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05387.
    PubMed     Abstract available


  436. PEARSON A, Booker A, Tio M, Marx G, et al
    Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study.
    Breast Cancer Res Treat. 2019 Aug 3. pii: 10.1007/s10549-019-05384.
    PubMed     Abstract available


  437. ALTUNDAG K
    HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features.
    Breast Cancer Res Treat. 2019;176:719.
    PubMed    


  438. ZDRAVKOVIC D, Ivanovic N, Crnokrak B
    Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision?
    Breast Cancer Res Treat. 2019;176:717.
    PubMed    


  439. ZHANG L, Bailleul J, Yazal T, Dong K, et al
    PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
    Breast Cancer Res Treat. 2019 Aug 1. pii: 10.1007/s10549-019-05376.
    PubMed     Abstract available


  440. ANGARITA FA, Dossa F, Zuckerman J, McCready DR, et al
    Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2019;177:215-224.
    PubMed     Abstract available


  441. HELLAND T, Hagen KB, Haugstoyl ME, Kvaloy JT, et al
    Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.
    Breast Cancer Res Treat. 2019;177:185-195.
    PubMed     Abstract available


  442. MARMOR S, Altman AM, Mayleben WT, Hui JYC, et al
    The use of contralateral prophylactic mastectomy among elderly patients in the United States.
    Breast Cancer Res Treat. 2019;177:175-183.
    PubMed     Abstract available


  443. CHEN XY, Yeong J, Thike AA, Bay BH, et al
    Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2019;177:17-27.
    PubMed     Abstract available


  444. ALTUNDAG K
    ER(+)/HER2(+) and ER-/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019;177:233.
    PubMed    


  445. MALTONI R, Bravaccini S
    What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
    Breast Cancer Res Treat. 2019;177:231-232.
    PubMed    


    July 2019
  446. ABRAMSON VG, Oliveira M, Cervantes A, Wildiers H, et al
    A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jul 31. pii: 10.1007/s10549-019-05360.
    PubMed     Abstract available


  447. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05370.
    PubMed     Abstract available


  448. ZHOU H, Wang XJ, Jiang X, Qian Z, et al
    Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05375.
    PubMed     Abstract available


  449. GOTTSCHAU M, Jensen A, Reinholdt K, Guleria S, et al
    Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05369.
    PubMed     Abstract available


  450. HUANG W, Ran R, Shao B, Li H, et al
    Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 Jul 29. pii: 10.1007/s10549-019-05371.
    PubMed     Abstract available


  451. DEL RE M, Bertolini I, Crucitta S, Fontanelli L, et al
    Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Jul 26. pii: 10.1007/s10549-019-05365.
    PubMed     Abstract available


  452. KIM EK, Park AK, Ko E, Park WY, et al
    Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05366.
    PubMed     Abstract available


  453. VROMANS R, Tenfelde K, Pauws S, van Eenbergen M, et al
    Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05351.
    PubMed     Abstract available


  454. ZHOU K, Li J, Li X
    Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05368.
    PubMed     Abstract available


  455. SAYYAD MR, Puchalapalli M, Vergara NG, Wangensteen SM, et al
    Syndecan-1 facilitates breast cancer metastasis to the brain.
    Breast Cancer Res Treat. 2019 Jul 20. pii: 10.1007/s10549-019-05347.
    PubMed     Abstract available


  456. DE GLAS N, Bastiaannet E, de Boer A, Siesling S, et al
    Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05356.
    PubMed     Abstract available


  457. ADEMUYIWA FO, Salyer P, Ma Y, Fisher S, et al
    Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05359.
    PubMed     Abstract available


  458. SAKAI T, Ozkurt E, DeSantis S, Wong SM, et al
    National trends of synchronous bilateral breast cancer incidence in the United States.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05363.
    PubMed     Abstract available


  459. HUERTA JM, Molina AJ, Chirlaque MD, Yepes P, et al
    Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study.
    Breast Cancer Res Treat. 2019 Jul 17. pii: 10.1007/s10549-019-05358.
    PubMed     Abstract available


  460. NAM SE, Lim W, Jeong J, Lee S, et al
    The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
    Breast Cancer Res Treat. 2019 Jul 16. pii: 10.1007/s10549-019-05357.
    PubMed     Abstract available


  461. ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
    Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 12. pii: 10.1007/s10549-019-05348.
    PubMed     Abstract available


  462. JOHNSON HM, Irish W, Muzaffar M, Vohra NA, et al
    Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05353.
    PubMed     Abstract available


  463. JACOT W, Dalenc F, Lopez-Crapez E, Chaltiel L, et al
    PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05349.
    PubMed     Abstract available


  464. ALEIXO GFP, Williams GR, Nyrop KA, Muss HB, et al
    Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05352.
    PubMed     Abstract available


  465. KUROZUMI S, Kaira K, Matsumoto H, Hirakata T, et al
    beta2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jul 9. pii: 10.1007/s10549-019-05341.
    PubMed     Abstract available


  466. MURATA T, Yanagisawa T, Kurihara T, Kaneko M, et al
    Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
    Breast Cancer Res Treat. 2019 Jul 8. pii: 10.1007/s10549-019-05330.
    PubMed     Abstract available


  467. MARINO MA, Gucalp A, Leithner D, Keating D, et al
    Mammographic screening in male patients at high risk for breast cancer: is it worth it?
    Breast Cancer Res Treat. 2019 Jul 6. pii: 10.1007/s10549-019-05338.
    PubMed     Abstract available


  468. YEO W, Ueno T, Lin CH, Liu Q, et al
    Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05318.
    PubMed     Abstract available


  469. HARBORG S, Cronin-Fenton DP, Borgquist S
    RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05337.
    PubMed    


  470. COUGHLIN SS
    Social determinants of breast cancer risk, stage, and survival.
    Breast Cancer Res Treat. 2019 Jul 3. pii: 10.1007/s10549-019-05340.
    PubMed     Abstract available


  471. ZEINDLER J, Angehrn F, Droeser R, Daster S, et al
    Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05336.
    PubMed     Abstract available


  472. SASADA S, Shiroma N, Goda N, Kajitani K, et al
    The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05339.
    PubMed     Abstract available


  473. BAS O, Dizdar O
    Classifying sarcopenia: using median value or cut-off values?
    Breast Cancer Res Treat. 2019;176:479.
    PubMed    


  474. GIANNAKEAS V, Narod SA
    A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05334.
    PubMed     Abstract available


  475. PUVANESARAJAH S, Gapstur SM, Patel AV, Sherman ME, et al
    Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05322.
    PubMed     Abstract available


  476. BEUGELS J, Meijvogel JLW, Tuinder SMH, Tjan-Heijnen VCG, et al
    The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions.
    Breast Cancer Res Treat. 2019;176:367-375.
    PubMed     Abstract available


  477. WEISS A, Lin H, Babiera GV, Bedrosian I, et al
    Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.
    Breast Cancer Res Treat. 2019;176:435-444.
    PubMed     Abstract available


  478. DUAZO-CASSIN L, Le Guellec S, Lusque A, Chantalat E, et al
    Breast desmoid tumor management in France: toward a new strategy.
    Breast Cancer Res Treat. 2019;176:329-335.
    PubMed     Abstract available


  479. BOUNDOUKI G, Wong Sik Hee JR, Croghan N, Stocking K, et al
    Comparing long-term local recurrence rates of surgical and non-surgical management of close anterior margins in breast conserving surgery.
    Breast Cancer Res Treat. 2019;176:311-319.
    PubMed     Abstract available


  480. RODRIGUES-DUARTE H, van Nijnatten TJA, Khoury T, Cody H, et al
    Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?
    Breast Cancer Res Treat. 2019;176:401-406.
    PubMed     Abstract available


  481. SPERANSKY S, Serafini P, Caroli J, Bicciato S, et al
    A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
    Breast Cancer Res Treat. 2019;176:271-289.
    PubMed     Abstract available


  482. MENG P, Vaapil M, Tagmount A, Loguinov A, et al
    Propagation of functional estrogen receptor positive normal human breast cells in 3D cultures.
    Breast Cancer Res Treat. 2019;176:131-140.
    PubMed     Abstract available


  483. LEE J, Kim HE, Song YS, Cho EY, et al
    miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
    Breast Cancer Res Treat. 2019;176:119-130.
    PubMed     Abstract available


  484. BAEZ-VALLECILLO L, Raghavendra AS, Hess KR, Barcenas CH, et al
    Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
    Breast Cancer Res Treat. 2019;176:227-234.
    PubMed     Abstract available


  485. NEALON K, Rebello M, Sobti N, Sherburne A, et al
    Improving surgical efficiency of immediate implant-based breast reconstruction following mastectomy.
    Breast Cancer Res Treat. 2019;176:159-164.
    PubMed     Abstract available


  486. MONTAGNE L, Gal J, Chand ME, Schiappa R, et al
    GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.
    Breast Cancer Res Treat. 2019;176:149-157.
    PubMed     Abstract available


    June 2019
  487. LI E, Guida JL, Tian Y, Sung H, et al
    Associations between mammographic density and tumor characteristics in Chinese women with breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05325.
    PubMed     Abstract available


  488. KOROBEYNIKOV V, Borakove M, Feng Y, Wuest WM, et al
    Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05329.
    PubMed     Abstract available


  489. MICHEL LL, Sommer L, Gonzalez Silos R, Lorenzo Bermejo J, et al
    Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05314.
    PubMed     Abstract available


  490. NEWELL M, Goruk S, Mazurak V, Postovit L, et al
    Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05331.
    PubMed     Abstract available


  491. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05328.
    PubMed     Abstract available


  492. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05332.
    PubMed     Abstract available


  493. FORNVIK D, Aaltonen KE, Chen Y, George AM, et al
    Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05326.
    PubMed     Abstract available


  494. GRANT CV, Carver CM, Hastings SD, Ramachandran K, et al
    Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
    Breast Cancer Res Treat. 2019 Jun 22. pii: 10.1007/s10549-019-05324.
    PubMed     Abstract available


  495. ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
    Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 20. pii: 10.1007/s10549-019-05313.
    PubMed     Abstract available


  496. TURTURRO SB, Najor MS, Yung T, Portt L, et al
    Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
    Breast Cancer Res Treat. 2019 Jun 17. pii: 10.1007/s10549-019-05320.
    PubMed     Abstract available


  497. SHAWKY MS, Huo CW, Henderson MA, Redfern A, et al
    A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.
    Breast Cancer Res Treat. 2019 Jun 8. pii: 10.1007/s10549-019-05300.
    PubMed     Abstract available


  498. OLIAI C, Douek ML, Rhoane C, Bhutada A, et al
    Clinical features of pseudocirrhosis in metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05311.
    PubMed     Abstract available


  499. NAYAK D, Katoch A, Sharma D, Faheem MM, et al
    Indolylkojyl methane analogue IKM5 potentially inhibits invasion of breast cancer cells via attenuation of GRP78.
    Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05301.
    PubMed     Abstract available


  500. DIERAS V, Bonnefoi H, Alba E, Awada A, et al
    Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05305.
    PubMed     Abstract available


  501. BHANDARI S, Ngo P, Kute B, Mandadi M, et al
    Adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging: a pilot study.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05308.
    PubMed     Abstract available


  502. MELISKO ME, Assefa M, Hwang J, DeLuca A, et al
    Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05309.
    PubMed     Abstract available


  503. LAO C, Lawrenson R, Edwards M, Campbell I, et al
    Treatment and survival of Asian women diagnosed with breast cancer in New Zealand.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05310.
    PubMed     Abstract available


  504. JERUSALEM G, Lancellotti P, Kim SB
    HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05303.
    PubMed     Abstract available


  505. TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
    Correction to: Racial disparities in surveillance mammography among older breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05291.
    PubMed     Abstract available


  506. MURPHY JD, Sandler D, White AJ, O'Brien KM, et al
    Severe acne and risk of breast cancer.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05302.
    PubMed     Abstract available


  507. WOLFF JL, Aufill J, Echavarria D, Heughan JA, et al
    Sharing in care: engaging care partners in the care and communication of breast cancer patients.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05306.
    PubMed     Abstract available


  508. PLASTERER C, Tsaih SW, Peck AR, Chervoneva I, et al
    Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05307.
    PubMed     Abstract available


  509. MCCLELLAND S 3RD, Rhome RM, Zellars RC
    Radiation oncology crossword: breast cancer.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05304.
    PubMed    


  510. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05292.
    PubMed     Abstract available


  511. ELFGEN C, Varga Z, Reeve K, Moskovszky L, et al
    The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05298.
    PubMed     Abstract available


  512. POODT IGM, Schipper RJ, de Greef BTA, Vugts G, et al
    Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval.
    Breast Cancer Res Treat. 2019;175:419-428.
    PubMed     Abstract available


  513. SHECKTER CC, Matros E, Lee GK, Selber JC, et al
    Applying a value-based care framework to post-mastectomy reconstruction.
    Breast Cancer Res Treat. 2019;175:547-551.
    PubMed     Abstract available


  514. WILLOUGHBY LI, D'Abbondanza JA, Baltzer HL, Mahoney JL, et al
    Body mass index impacts infection rates in immediate autogenous breast reconstruction.
    Breast Cancer Res Treat. 2019;175:765-773.
    PubMed     Abstract available


  515. BOLAM KA, Mijwel S, Rundqvist H, Wengstrom Y, et al
    Two-year follow-up of the OptiTrain randomised controlled exercise trial.
    Breast Cancer Res Treat. 2019;175:637-648.
    PubMed     Abstract available


  516. FONT R, Espinas JA, Barnadas A, Izquierdo A, et al
    Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
    Breast Cancer Res Treat. 2019;175:733-740.
    PubMed     Abstract available


  517. FIGURA NB, Rizk VT, Mohammadi H, Evernden B, et al
    Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
    Breast Cancer Res Treat. 2019;175:781-788.
    PubMed     Abstract available


  518. CLIFTON K, Min Y, Kimmel J, Litton J, et al
    Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.
    Breast Cancer Res Treat. 2019;175:667-674.
    PubMed     Abstract available


  519. DEKLERCK E, Denys H, Kreps EO
    Corneal features in trastuzumab emtansine treatment: not a rare occurrence.
    Breast Cancer Res Treat. 2019;175:525-530.
    PubMed     Abstract available


  520. MCCLELLAND S 3RD, Hatfield J, Degnin C, Chen Y, et al
    Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma.
    Breast Cancer Res Treat. 2019;175:409-418.
    PubMed     Abstract available


  521. IGNATOV T, Gorbunow F, Eggemann H, Ortmann O, et al
    Loss of HER2 after HER2-targeted treatment.
    Breast Cancer Res Treat. 2019;175:401-408.
    PubMed     Abstract available


    May 2019
  522. RUIZ-BORREGO M, Guerrero-Zotano A, Bermejo B, Ramos M, et al
    Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05296.
    PubMed     Abstract available


  523. JOZSA F, Ahmed M, Baker R, Douek M, et al
    Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05299.
    PubMed     Abstract available


  524. SAW S, Lim J, Lim SH, Wong M, et al
    Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05290.
    PubMed     Abstract available


  525. ROSENBERG SM, Vaz-Luis I, Gong J, Rajagopal PS, et al
    Employment trends in young women following a breast cancer diagnosis.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05293.
    PubMed     Abstract available


  526. KRYSTEL-WHITTEMORE M, Xu J, Brogi E, Ventura K, et al
    Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2019 May 29. pii: 10.1007/s10549-019-05295.
    PubMed     Abstract available


  527. LAMBERTINI M, Campbell C, Gelber RD, Viale G, et al
    Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
    Breast Cancer Res Treat. 2019 May 27. pii: 10.1007/s10549-019-05284.
    PubMed     Abstract available


  528. ENGMANN NJ, Scott CG, Jensen MR, Winham S, et al
    Combined effect of volumetric breast density and body mass index on breast cancer risk.
    Breast Cancer Res Treat. 2019 May 25. pii: 10.1007/s10549-019-05283.
    PubMed     Abstract available


  529. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05285.
    PubMed     Abstract available


  530. BASULAIMAN B, Awan AA, Fergusson D, Vandermeer L, et al
    Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05274.
    PubMed     Abstract available


  531. PINEDA-MONCUSI M, Servitja S, Tusquets I, Diez-Perez A, et al
    Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05289.
    PubMed     Abstract available


  532. DONG B, Xie C, Jing X, Lin L, et al
    Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05278.
    PubMed     Abstract available


  533. PRAWIRA A, Munusamy P, Yuan J, Chan CHT, et al
    Assessment of PARP4 as a candidate breast cancer susceptibility gene.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05286.
    PubMed     Abstract available


  534. AL-HILLI Z, Choong G, Keeney MG, Visscher DW, et al
    Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05264.
    PubMed     Abstract available


  535. HEDRICK E, Li X, Cheng Y, Lacey A, et al
    Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05279.
    PubMed     Abstract available


  536. TURKKI R, Byckhov D, Lundin M, Isola J, et al
    Breast cancer outcome prediction with tumour tissue images and machine learning.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05281.
    PubMed     Abstract available


  537. POMPONIO MK, Keele LJ, Fox KR, Clark AS, et al
    Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05282.
    PubMed     Abstract available


  538. DECKER T, Marschner N, Muendlein A, Welt A, et al
    VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
    Breast Cancer Res Treat. 2019 May 21. pii: 10.1007/s10549-019-05280.
    PubMed     Abstract available


  539. JONGEN L, Floris G, Wildiers H, Claessens F, et al
    Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 May 20. pii: 10.1007/s10549-019-05252.
    PubMed     Abstract available


  540. ZHANG JY, Liao YH, Lin Y, Liu Q, et al
    Effects of tea consumption and the interactions with lipids on breast cancer survival.
    Breast Cancer Res Treat. 2019 May 16. pii: 10.1007/s10549-019-05253.
    PubMed     Abstract available


  541. SILBERHOLZ J, Bertsimas D, Vahdat L
    Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 14. pii: 10.1007/s10549-019-05208.
    PubMed     Abstract available


  542. PILEVARZADEH M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, et al
    Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05271.
    PubMed     Abstract available


  543. LI YR, Ro V, Steel L, Carrigan E, et al
    Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05267.
    PubMed     Abstract available


  544. AWAN AA, Hutton B, Hilton J, Mazzarello S, et al
    De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05265.
    PubMed     Abstract available


  545. SHENG JY, Blackford AL, Bardia A, Venkat R, et al
    Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05270.
    PubMed     Abstract available


  546. GOLDBERG M, Sutradhar R, Paszat L, Whelan TJ, et al
    Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis.
    Breast Cancer Res Treat. 2019 May 10. pii: 10.1007/s10549-019-05266.
    PubMed     Abstract available


  547. AZRAD M, Blair CK, Rock CL, Sedjo RL, et al
    Adult weight gain accelerates the onset of breast cancer.
    Breast Cancer Res Treat. 2019 May 9. pii: 10.1007/s10549-019-05268.
    PubMed     Abstract available


  548. MORI H, Kubo M, Kai M, Yamada M, et al
    T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05256.
    PubMed     Abstract available


  549. FONTAINE C, Renard V, Van den Bulk H, Vuylsteke P, et al
    Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
    Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05259.
    PubMed     Abstract available


  550. LUX MP, Bohme S, Hucherig S, Jeratsch U, et al
    Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05262.
    PubMed     Abstract available


  551. CAZZANIGA ME, Danesi R, Girmenia C, Invernizzi P, et al
    Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05261.
    PubMed     Abstract available


  552. AARTS BM, Klompenhouwer EG, Dresen RC, Laenen A, et al
    Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05254.
    PubMed     Abstract available


  553. COHEN EN, Fouad TM, Lee BN, Arun BK, et al
    Elevated serum levels of sialyl Lewis X (sLe(X)) and inflammatory mediators in patients with breast cancer.
    Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05258.
    PubMed     Abstract available


  554. IRENE SU H, Stark S, Kwan B, Boles S, et al
    Efficacy of a web-based women's health survivorship care plan for young breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05260.
    PubMed     Abstract available


  555. ELFGEN C, Montagna G, Schmid SM, Bierbauer W, et al
    Noncompliance with palliative systemic therapy in patients with distant metastatic breast cancer: a blind spot for oncologists?
    Breast Cancer Res Treat. 2019 May 2. pii: 10.1007/s10549-019-05255.
    PubMed     Abstract available


  556. SAVVA C, De Souza K, Ali R, Rakha EA, et al
    Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Breast Cancer Res Treat. 2019;175:105-115.
    PubMed     Abstract available


  557. JUNG J, Han W, Lee ES, Jung SY, et al
    Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Breast Cancer Res Treat. 2019;175:203-215.
    PubMed     Abstract available


    April 2019
  558. BAKER HA, Fabian CJ, Hastings RC, Dixon DA, et al
    Circulating adipose stromal cells as a response biomarker in phase II energy balance trials of obese breast cancer survivors and high-risk women.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05251.
    PubMed     Abstract available


  559. WAGONER CW, Choi SK, Deal AM, Lee JT, et al
    Establishing physical activity in breast cancer: self-report versus activity tracker.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05263.
    PubMed     Abstract available


  560. SESTAK I, Martin M, Dubsky P, Kronenwett R, et al
    Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05226.
    PubMed     Abstract available


  561. ACKLAND SP, Gebski V, Zdenkowski N, Wilson A, et al
    Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05187.
    PubMed     Abstract available


  562. TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
    Racial disparities in surveillance mammography among older breast cancer survivors.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05250.
    PubMed     Abstract available


  563. KIM JY, Lee DW, Lee KH, Min A, et al
    Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05249.
    PubMed     Abstract available


  564. ROTTER J, Wilson L, Greiner MA, Pollack CE, et al
    Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05248.
    PubMed     Abstract available


  565. ABU-KHALAF MM, Safonov A, Stratton J, Wang S, et al
    Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05178.
    PubMed     Abstract available


  566. LEE HM, Kim BW, Park S, Park S, et al
    Childbirth in young Korean women with previously treated breast cancer: The SMARTSHIP study.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05244.
    PubMed     Abstract available


  567. WANG M, Chen H, Wu K, Ding A, et al
    Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case-control analysis.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05240.
    PubMed     Abstract available


  568. SAMBADE MJ, Prince G, Deal AM, Trembath D, et al
    Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
    Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05211.
    PubMed     Abstract available


  569. ALTUNDAG K
    Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?
    Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05220.
    PubMed    


  570. SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
    Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.
    Breast Cancer Res Treat. 2019 Apr 22. pii: 10.1007/s10549-019-05237.
    PubMed     Abstract available


  571. GAO C, Yuan X, Jiang Z, Gan D, et al
    Regulation of AKT phosphorylation by GSK3beta and PTEN to control chemoresistance in breast cancer.
    Breast Cancer Res Treat. 2019 Apr 20. pii: 10.1007/s10549-019-05239.
    PubMed     Abstract available


  572. BELLON JR, Guo H, Barry WT, Dang CT, et al
    Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
    Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05238.
    PubMed     Abstract available


  573. BAHRI N, Fathi Najafi T, Homaei Shandiz F, Tohidinik HR, et al
    The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies.
    Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05231.
    PubMed     Abstract available


  574. NOORDHOEK I, de Groot AF, Cohen D, Liefers GJ, et al
    Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05233.
    PubMed     Abstract available


  575. KHAN KA, Mazuquin B, Canaway A, Petrou S, et al
    Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05235.
    PubMed     Abstract available


  576. FLORES-DIAZ D, Arce C, Flores-Luna L, Reynoso-Noveron N, et al
    Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05234.
    PubMed     Abstract available


  577. MA X, Dang C, Min W, Diao Y, et al
    Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05189.
    PubMed     Abstract available


  578. LEE J, Lim B, Pearson T, Choi K, et al
    Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05218.
    PubMed     Abstract available


  579. CHEN BT, Jin T, Patel SK, Ye N, et al
    Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05230.
    PubMed     Abstract available


  580. CAGNEY DN, Lamba N, Montoya S, Li P, et al
    Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05236.
    PubMed     Abstract available


  581. DARCEY E, Lloyd R, Cadby G, Pilkington L, et al
    The association between mammographic density and breast cancer risk in Western Australian Aboriginal women.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05225.
    PubMed     Abstract available


  582. BERNSTEIN-MOLHO R, Singer A, Laitman Y, Netzer I, et al
    Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05228.
    PubMed     Abstract available


  583. MUTONGA M, Speedy S, Rademaker A, Liu D, et al
    Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 11. pii: 10.1007/s10549-018-05088.
    PubMed     Abstract available


  584. VAN UDEN DJP, van Maaren MC, Bult P, Strobbe LJA, et al
    Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05219.
    PubMed     Abstract available


  585. NEUNER JM, Nattinger AB, Yen T, McGinley E, et al
    Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05213.
    PubMed     Abstract available


  586. KREUTZ C, Schmidt ME, Steindorf K
    Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05217.
    PubMed     Abstract available


  587. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05223.
    PubMed     Abstract available


  588. LU Y, Li J, Zhao X, Li J, et al
    Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm.
    Breast Cancer Res Treat. 2019 Apr 5. pii: 10.1007/s10549-019-05202.
    PubMed     Abstract available


  589. KUSAMA H, Shimoda M, Miyake T, Tanei T, et al
    Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.
    Breast Cancer Res Treat. 2019 Apr 4. pii: 10.1007/s10549-019-05222.
    PubMed     Abstract available


  590. EVANS DGR, Harkness EF, Brentnall AR, van Veen EM, et al
    Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05210.
    PubMed     Abstract available


  591. KUROZUMI S, Joseph C, Raafat S, Sonbul S, et al
    Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05216.
    PubMed     Abstract available


  592. WANG G, Qin S, Zayas J, Ingle JN, et al
    4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05194.
    PubMed     Abstract available


  593. LIN Y, Wang C, Huang X, Zhou X, et al
    Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05207.
    PubMed     Abstract available


    March 2019
  594. KORZETS Y, Fyles A, Shepshelovich D, Amir E, et al
    Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Mar 30. pii: 10.1007/s10549-019-05209.
    PubMed     Abstract available


  595. DANIELL KM, Bardia A, Sun F, Roberts SA, et al
    Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Mar 27. pii: 10.1007/s10549-019-05206.
    PubMed     Abstract available


  596. AURIT SJ, Devesa SS, Soliman AS, Schairer C, et al
    Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).
    Breast Cancer Res Treat. 2019 Mar 26. pii: 10.1007/s10549-019-05193.
    PubMed     Abstract available


  597. TORRES A, Ramdial JL, Aguirre LE, Mahtani R, et al
    Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05203.
    PubMed     Abstract available


  598. CAMARA RJA, Schwentner L, Friedl TWP, Deniz M, et al
    Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05171.
    PubMed     Abstract available


  599. CAO W, Xie Y, He Y, Li J, et al
    Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05199.
    PubMed     Abstract available


  600. VARELLA L, Eziokwu AS, Jia X, Kruse M, et al
    Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05176.
    PubMed     Abstract available


  601. HOSIO M, Urpilainen E, Marttila M, Hautakoski A, et al
    Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05185.
    PubMed     Abstract available


  602. DAVIS LE, Fulton C, Bubis LD, Sussman J, et al
    Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
    Breast Cancer Res Treat. 2019 Mar 16. pii: 10.1007/s10549-019-05196.
    PubMed     Abstract available


  603. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
    Breast Cancer Res Treat. 2019 Mar 14. pii: 10.1007/s10549-019-05200.
    PubMed     Abstract available


  604. YU C, Qin N, Pu Z, Song C, et al
    Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05177.
    PubMed     Abstract available


  605. MARSCHNER N, Trarbach T, Rauh J, Meyer D, et al
    Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05197.
    PubMed     Abstract available


  606. DE GROOT AF, Blok EJ, Charehbili A, Engels CC, et al
    Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05195.
    PubMed     Abstract available


  607. FASCHING PA, Gass P, Haberle L, Volz B, et al
    Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05198.
    PubMed     Abstract available


  608. TIAN J, Chen X, Fu S, Zhang R, et al
    Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05183.
    PubMed     Abstract available


  609. LYNCE F, Barac A, Geng X, Dang C, et al
    Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05191.
    PubMed     Abstract available


  610. CHRISCHILLES EA, Riley D, Letuchy E, Koehler L, et al
    Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05184.
    PubMed     Abstract available


  611. ZHANG B, Long EF
    Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05190.
    PubMed     Abstract available


  612. PLAVC G, Ratosa I, Zagar T, Zadnik V, et al
    Explaining variation in quality of breast cancer care and its impact: a nationwide population-based study from Slovenia.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05186.
    PubMed     Abstract available


  613. KAISER K, Cameron KA, Beaumont J, Garcia SF, et al
    What does risk of future cancer mean to breast cancer patients?
    Breast Cancer Res Treat. 2019 Mar 6. pii: 10.1007/s10549-019-05182.
    PubMed     Abstract available


  614. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    ERalpha upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-kappaB in breast cancer.
    Breast Cancer Res Treat. 2019 Mar 4. pii: 10.1007/s10549-018-05108.
    PubMed     Abstract available


  615. DOEGE D, Thong MS, Koch-Gallenkamp L, Bertram H, et al
    Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05188.
    PubMed     Abstract available


  616. LEE J, Lim B, Pearson T, Choi K, et al
    Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05166.
    PubMed     Abstract available


  617. VAN DOOIJEWEERT C, Deckers IAG, Baas IO, van der Wall E, et al
    Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
    Breast Cancer Res Treat. 2019 Mar 1. pii: 10.1007/s10549-019-05180.
    PubMed     Abstract available


    February 2019
  618. AFZALI F, Akbari P, Naderi-Manesh H, Gardaneh M, et al
    The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
    Breast Cancer Res Treat. 2019 Feb 27. pii: 10.1007/s10549-019-05159.
    PubMed     Abstract available


  619. MARKS DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, et al
    The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05169.
    PubMed     Abstract available


  620. SAGAWA N, Ohno S, Hiratsuka T, Kondo N, et al
    The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05164.
    PubMed     Abstract available


  621. RICE SR, Feigenberg SJ, Hamza M, Molitoris JK, et al
    Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05150.
    PubMed     Abstract available


  622. ACETO GM, Awadelkarim KD, Di Nicola M, Moscatello C, et al
    Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05168.
    PubMed     Abstract available


  623. TICE JA, Bissell MCS, Miglioretti DL, Gard CC, et al
    Validation of the breast cancer surveillance consortium model of breast cancer risk.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05167.
    PubMed     Abstract available


  624. WUERSTLEIN R, Kates R, Gluz O, Grischke EM, et al
    Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-018-05075.
    PubMed     Abstract available


  625. GUO L, Chen G, Zhang W, Zhou L, et al
    A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Breast Cancer Res Treat. 2019 Feb 19. pii: 10.1007/s10549-019-05135.
    PubMed     Abstract available


  626. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Feb 15. pii: 10.1007/s10549-019-05165.
    PubMed     Abstract available


  627. KOTSOPOULOS J, Lubinski J, Lynch HT, Tung N, et al
    Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05162.
    PubMed     Abstract available


  628. STAVRAKA C, Pouptsis A, Okonta L, DeSouza K, et al
    Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05144.
    PubMed     Abstract available


  629. GREGOROWITSCH ML, Ghedri A, Young-Afat DA, Bijlsma R, et al
    The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05149.
    PubMed     Abstract available


  630. YANG SX, Polley EC
    Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05142.
    PubMed     Abstract available


  631. LAN Y, Zhao E, Luo S, Xiao Y, et al
    Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
    Breast Cancer Res Treat. 2019 Feb 9. pii: 10.1007/s10549-019-05153.
    PubMed     Abstract available


  632. O'MEARA T, Safonov A, Casadevall D, Qing T, et al
    Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05156.
    PubMed     Abstract available


  633. BICK U, Engel C, Krug B, Heindel W, et al
    High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05152.
    PubMed     Abstract available


  634. LIU Y, Pandey PR, Sharma S, Xing F, et al
    ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-018-05126.
    PubMed     Abstract available


  635. HUSSAIN Y, Drill E, Dang CT, Liu JE, et al
    Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05139.
    PubMed     Abstract available


  636. DICKINSON SL, Golzarri-Arroyo L, Brown AW, McComb B, et al
    Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEA
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05155.
    PubMed    


  637. SUN M, Wu D, Zhou K, Li H, et al
    An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Breast Cancer Res Treat. 2019 Feb 4. pii: 10.1007/s10549-019-05147.
    PubMed     Abstract available


  638. LIGABUE MB, Campanini I, Veroni P, Cepelli A, et al
    Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05136.
    PubMed     Abstract available


  639. LIU ZH, Wang K, Lin DY, Xu J, et al
    Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05148.
    PubMed     Abstract available


  640. ALTUNDAG K
    HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
    Breast Cancer Res Treat. 2019 Feb 1. pii: 10.1007/s10549-019-05151.
    PubMed    


  641. ESEN E, Aslan M, Sonbahar BC, Kerimoglu RS, et al
    YouTube English videos as a source of information on breast self-examination.
    Breast Cancer Res Treat. 2019;173:629-635.
    PubMed     Abstract available


  642. SILVER MI, Klein W, Samimi G, Minasian L, et al
    Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study((R)).
    Breast Cancer Res Treat. 2019;173:719-726.
    PubMed     Abstract available


  643. HEINEY SP, Parker PD, Felder TM, Adams SA, et al
    A systematic review of interventions to improve adherence to endocrine therapy.
    Breast Cancer Res Treat. 2019;173:499-510.
    PubMed     Abstract available


    January 2019
  644. FATEHI S, Maasoumi R, Atashsokhan G, Hamidzadeh A, et al
    The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Jan 30. pii: 10.1007/s10549-019-05140.
    PubMed     Abstract available


  645. SZIJGYARTO Z, Flach KD, Opdam M, Palmieri C, et al
    Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Breast Cancer Res Treat. 2019 Jan 24. pii: 10.1007/s10549-018-05110.
    PubMed     Abstract available


  646. CAMP NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, et al
    Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 23. pii: 10.1007/s10549-018-05097.
    PubMed     Abstract available


  647. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-019-05128.
    PubMed     Abstract available


  648. EL-ANSARI R, Craze ML, Alfarsi L, Soria D, et al
    The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-018-05111.
    PubMed     Abstract available


  649. WEISS A, Grossmith S, Cutts D, Mikami SA, et al
    Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05116.
    PubMed     Abstract available


  650. COOPEY SB, Kartal K, Li C, Yala A, et al
    Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05117.
    PubMed     Abstract available


  651. ROBERTSON S, Ronnlund C, de Boniface J, Hartman J, et al
    Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05119.
    PubMed     Abstract available


  652. PETRELLI F, Ghidini A, Pedersini R, Cabiddu M, et al
    Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-019-05133.
    PubMed     Abstract available


  653. XU X, Chlebowski RT, Shi J, Barac A, et al
    Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05086.
    PubMed     Abstract available


  654. BATTISTI NML, Kingston B, King J, Denton A, et al
    Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Breast Cancer Res Treat. 2019 Jan 17. pii: 10.1007/s10549-019-05134.
    PubMed     Abstract available


  655. FRIEDLAENDER A, Vuilleumier A, Viassolo V, Ayme A, et al
    BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 11. pii: 10.1007/s10549-018-05127.
    PubMed     Abstract available


  656. RUGO HS, Finn RS, Dieras V, Ettl J, et al
    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05125.
    PubMed     Abstract available


  657. HASHEMI SM, Balouchi A, Al-Mawali A, Rafiemanesh H, et al
    Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05131.
    PubMed     Abstract available


  658. GADALLA R, Hassan H, Ibrahim SA, Abdullah MS, et al
    Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05129.
    PubMed     Abstract available


  659. NITZ U, Gluz O, Christgen M, Kates RE, et al
    Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05105.
    PubMed     Abstract available


  660. STOVGAARD ES, Dyhl-Polk A, Roslind A, Balslev E, et al
    PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05130.
    PubMed     Abstract available


  661. LUBINSKI J, Huzarski T, Gronwald J, Cybulski C, et al
    Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
    Breast Cancer Res Treat. 2019 Jan 5. pii: 10.1007/s10549-018-05076.
    PubMed     Abstract available


  662. ALHUDIRI IM, Nolan CC, Ellis IO, Elzagheid A, et al
    Expression of Lamin A/C in early-stage breast cancer and its prognostic value.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05092.
    PubMed     Abstract available


  663. VANE MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, et al
    Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05074.
    PubMed     Abstract available


  664. BOWDEN AR, Tischkowitz M
    Clinical implications of germline mutations in breast cancer genes: RECQL.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05096.
    PubMed     Abstract available


  665. CHENG ES, Yu XQ
    Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05101.
    PubMed    


  666. AUSTIN AM, Kapadia NS, Brooks GA, Onega TL, et al
    Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05098.
    PubMed     Abstract available


  667. YAMAMOTO T, Kanaya N, Somlo G, Chen S, et al
    Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05104.
    PubMed     Abstract available


  668. YANG Z, Ouyang T, Li J, Wang T, et al
    Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05124.
    PubMed     Abstract available


  669. LUSTIG DB, Warburton R, Dingee CK, Kuusk U, et al
    Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05109.
    PubMed     Abstract available


  670. OCANA A, Gil-Martin M, Antolin S, Atienza M, et al
    Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05100.
    PubMed     Abstract available


  671. KENSLER KH, Eliassen AH, Rosner BA, Hankinson SE, et al
    Pre-diagnostic sex hormone levels and survival among breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05121.
    PubMed     Abstract available


  672. PATEL DA, Xi J, Luo J, Hassan B, et al
    Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05106.
    PubMed     Abstract available


  673. O'BRIEN P, Matheson K, Jeyakumar A, Anderson K, et al
    The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05114.
    PubMed     Abstract available


  674. KIM SJ, Zhang CXW, Demsky R, Armel S, et al
    Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05118.
    PubMed     Abstract available


  675. CARUANA E, Foucher Y, Tessier P, Frenel JS, et al
    Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05107.
    PubMed     Abstract available


  676. WUNDERLE M, Pretscher J, Brucker SY, Volz B, et al
    Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05115.
    PubMed     Abstract available


  677. GOGATE A, Rotter JS, Trogdon JG, Meng K, et al
    An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05099.
    PubMed     Abstract available


  678. HU J, Wang X, Guo S, Chen F, et al
    Peer support interventions for breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-5033.
    PubMed     Abstract available


    December 2018
  679. LYES MA, Payne S, Ferrell P, Pizzo SV, et al
    Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
    Breast Cancer Res Treat. 2018 Dec 29. pii: 10.1007/s10549-018-05103.
    PubMed     Abstract available


  680. THEBERGE I, Vandal N, Guertin MH, Perron L, et al
    The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Breast Cancer Res Treat. 2018 Dec 18. pii: 10.1007/s10549-018-05095.
    PubMed     Abstract available


  681. MALMGREN J, Hurlbert M, Atwood M, Kaplan HG, et al
    Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05090.
    PubMed     Abstract available


  682. BUTTON B, Croessmann S, Chu D, Rosen DM, et al
    The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05087.
    PubMed     Abstract available


  683. KIM JH, Yoon KH, Hur H, Park S, et al
    Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05091.
    PubMed     Abstract available


  684. JOSEPH C, Arshad M, Kurozomi S, Althobiti M, et al
    Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2018 Dec 15. pii: 10.1007/s10549-018-05085.
    PubMed     Abstract available


  685. JOHANSSON ALV, Weibull CE, Fredriksson I, Lambe M, et al
    Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05083.
    PubMed     Abstract available


  686. DURAN-LOZANO L, Montalban G, Bonache S, Moles-Fernandez A, et al
    Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05094.
    PubMed     Abstract available


  687. RAGHAVENDRA A, Wecsler J, Ji L, Sheth P, et al
    Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    Breast Cancer Res Treat. 2018 Dec 12. pii: 10.1007/s10549-018-05084.
    PubMed     Abstract available


  688. WANG XM, Zhang Z, Pan LH, Cao XC, et al
    KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2018 Dec 8. pii: 10.1007/s10549-018-05069.
    PubMed     Abstract available


  689. NANNI O, Amadori D, De Censi A, Rocca A, et al
    Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
    Breast Cancer Res Treat. 2018 Dec 7. pii: 10.1007/s10549-018-05070.
    PubMed     Abstract available


  690. PARANJPE R, John G, Trivedi M, Abughosh S, et al
    Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 6. pii: 10.1007/s10549-018-05073.
    PubMed     Abstract available


  691. DONENBERG T, George S, Ali J, Bravo G, et al
    A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Breast Cancer Res Treat. 2018 Dec 4. pii: 10.1007/s10549-018-5045.
    PubMed     Abstract available


  692. COUGHLIN SS, Paxton RJ, Moore N, Stewart JL, et al
    Survivorship issues in older breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 1. pii: 10.1007/s10549-018-05078.
    PubMed     Abstract available


  693. MCCLATCHY DM 3RD, Zuurbier RA, Wells WA, Paulsen KD, et al
    Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology.
    Breast Cancer Res Treat. 2018;172:587-595.
    PubMed     Abstract available


  694. MCMULLEN ER, Gonzalez ME, Skala SL, Tran M, et al
    CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.
    Breast Cancer Res Treat. 2018;172:577-586.
    PubMed     Abstract available


    November 2018
  695. LIDBRINK E, Chmielowska E, Otremba B, Bouhlel A, et al
    A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
    Breast Cancer Res Treat. 2018 Nov 30. pii: 10.1007/s10549-018-5058.
    PubMed     Abstract available


  696. WALSH EM, Shalaby A, O'Loughlin M, Keane N, et al
    Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Breast Cancer Res Treat. 2018 Nov 28. pii: 10.1007/s10549-018-5066.
    PubMed     Abstract available


  697. HOLLERN DP, Contreras CM, Dance-Barnes S, Silva GO, et al
    A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5061.
    PubMed     Abstract available


  698. SHTAM T, Naryzhny S, Samsonov R, Karasik D, et al
    Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5043.
    PubMed     Abstract available


  699. ABOUEGYLAH M, Braunstein LZ, Alm El-Din MA, Niemierko A, et al
    Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5053.
    PubMed     Abstract available


  700. GIBBS LD, Chaudhary P, Mansheim K, Hare RJ, et al
    ANXA2 expression in African American triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5030.
    PubMed     Abstract available


  701. IGNATOV T, Claus M, Nass N, Haybaeck J, et al
    G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5064.
    PubMed     Abstract available


  702. CHASAMPALIOTI M, Green AR, Ellis IO, Rakha EA, et al
    Connexin 43 is an independent predictor of patient outcome in breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5063.
    PubMed     Abstract available


  703. HENRY DA, Lee MC, Almanza D, Ahmed KA, et al
    Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5057.
    PubMed     Abstract available


  704. CRAZE ML, El-Ansari R, Aleskandarany MA, Cheng KW, et al
    Glutamate dehydrogenase (GLUD1) expression in breast cancer.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5060.
    PubMed     Abstract available


  705. LOO LWM, Gao C, Shvetsov YB, Okoro DR, et al
    MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5065.
    PubMed     Abstract available


  706. WANG J, Xu B, Wang W, Zhai X, et al
    Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5047.
    PubMed     Abstract available


  707. ROZNER RN, Freites-Martinez A, Shapiro J, Geer EB, et al
    Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
    Breast Cancer Res Treat. 2018 Nov 22. pii: 10.1007/s10549-018-4996.
    PubMed     Abstract available


  708. DIBABA DT, Ogunsina K, Braithwaite D, Akinyemiju T, et al
    Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5056.
    PubMed     Abstract available


  709. HASKINS CB, McDowell BD, Carnahan RM, Fiedorowicz JG, et al
    Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5050.
    PubMed     Abstract available


  710. CAPARICA R, Bruzzone M, Poggio F, Ceppi M, et al
    Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5055.
    PubMed     Abstract available


  711. ZOOROB RJ, Salemi JL, Mejia de Grubb MC, Modak S, et al
    A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5059.
    PubMed     Abstract available


  712. LEE KWC, Lord S, Finn RS, Lim E, et al
    The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5054.
    PubMed     Abstract available


  713. CAO J, Eshak ES, Liu K, Muraki I, et al
    Sleep duration and risk of breast cancer: The JACC Study.
    Breast Cancer Res Treat. 2018 Nov 20. pii: 10.1007/s10549-018-4995.
    PubMed     Abstract available


  714. JONGEN L, Floris G, Boeckx B, Smeets D, et al
    Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5049.
    PubMed     Abstract available


  715. LIU J, Liu L, Yague E, Yang Q, et al
    GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5052.
    PubMed     Abstract available


  716. CORSO G, Pravettoni G, Galimberti V, Veronesi P, et al
    Clinical implication of E-cadherin deficiency in lobular breast cancer.
    Breast Cancer Res Treat. 2018 Nov 17. pii: 10.1007/s10549-018-5051.
    PubMed    


  717. XU R, Tang P, Li C
    Association between pre-operative magnetic resonance imaging (MRI) and surgical outcomes in breast cancer: not yet determined.
    Breast Cancer Res Treat. 2018 Nov 16. pii: 10.1007/s10549-018-5010.
    PubMed    


  718. BLEICHER RJ, Chang C, Wang CE, Goldstein LJ, et al
    Treatment delays from transfers of care and their impact on breast cancer quality measures.
    Breast Cancer Res Treat. 2018 Nov 15. pii: 10.1007/s10549-018-5046.
    PubMed     Abstract available


  719. MORTEN BC, Chiu S, Oldmeadow C, Lubinski J, et al
    The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Nov 14. pii: 10.1007/s10549-018-5039.
    PubMed     Abstract available


  720. DESANTIS CE, Ma J, Jemal A
    Trends in stage at diagnosis for young breast cancer patients in the United States.
    Breast Cancer Res Treat. 2018 Nov 13. pii: 10.1007/s10549-018-5042.
    PubMed     Abstract available


  721. KIM YH, Hwang JH, Bae JH, Choi JY, et al
    Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.
    Breast Cancer Res Treat. 2018 Nov 12. pii: 10.1007/s10549-018-5041.
    PubMed     Abstract available


  722. DROGEMOLLER BI, Wright GEB, Shih J, Monzon JG, et al
    CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5027.
    PubMed     Abstract available


  723. BUSCARIOLLO DL, Cronin AM, Borstelmann NA, Punglia RS, et al
    Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5006.
    PubMed     Abstract available


  724. GUDINA AT, Copeland G, Soliman AS, Hirko KA, et al
    Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5037.
    PubMed     Abstract available


  725. SKULI SJ, Sheng JY, Bantug ET, Zafman N, et al
    Survivorship care visits in a high-risk population of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5028.
    PubMed     Abstract available


  726. XUE C, Wei W, Sun P, Zheng W, et al
    Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-4997.
    PubMed     Abstract available


  727. HOPPE EJ, Hussain LR, Grannan KJ, Dunki-Jacobs EM, et al
    Racial disparities in breast cancer persist despite early detection: analysis of treatment of stage 1 breast cancer and effect of insurance status on disparities.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-5036.
    PubMed     Abstract available


  728. LI T, Yang J, Lv Y, Yin F, et al
    Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5029.
    PubMed     Abstract available


  729. PARK S, Moon BI, Oh SJ, Lee HB, et al
    Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5032.
    PubMed     Abstract available


  730. HENG YJ, Wang J, Ahearn TU, Brown SB, et al
    Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5034.
    PubMed     Abstract available


  731. SZOSTAKOWSKA M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A, et al
    Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5023.
    PubMed     Abstract available


  732. SUNG JS, Corben AD, Brooks JD, Edelweiss M, et al
    Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Breast Cancer Res Treat. 2018;172:487-496.
    PubMed     Abstract available


  733. NARAYAN AK, Elkin EB, Lehman CD, Morris EA, et al
    Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines.
    Breast Cancer Res Treat. 2018;172:463-468.
    PubMed     Abstract available


  734. SANCHEZ-SPITMAN AB, Dezentje VO, Swen JJ, Moes DJAR, et al
    Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
    Breast Cancer Res Treat. 2018;172:401-411.
    PubMed     Abstract available


  735. WU NC, Wong W, Ho KE, Chu VC, et al
    Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Breast Cancer Res Treat. 2018;172:327-338.
    PubMed     Abstract available


  736. REGMI S, Fung TS, Lim S, Luo KQ, et al
    Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells.
    Breast Cancer Res Treat. 2018;172:297-312.
    PubMed     Abstract available


  737. TUDINI E, Moghadasi S, Parsons MT, van der Kolk L, et al
    Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Breast Cancer Res Treat. 2018;172:497-503.
    PubMed     Abstract available


  738. YEAP PM, Evans A, Purdie CA, Jordan LB, et al
    A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma.
    Breast Cancer Res Treat. 2018;172:381-389.
    PubMed     Abstract available


  739. PAREKH A, Fu W, Hu C, Shen CJ, et al
    Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.
    Breast Cancer Res Treat. 2018;172:201-208.
    PubMed     Abstract available


  740. ALSHAKER H, Srivats S, Monteil D, Wang Q, et al
    Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
    Breast Cancer Res Treat. 2018;172:33-43.
    PubMed     Abstract available


  741. BARNES-KEDAR I, Bernstein-Molho R, Ginzach N, Hartmajer S, et al
    The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Breast Cancer Res Treat. 2018;172:151-157.
    PubMed     Abstract available


    October 2018
  742. YOON TI, Kwak BS, Yi OV, Kim S, et al
    Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
    Breast Cancer Res Treat. 2018 Oct 30. pii: 10.1007/s10549-018-5031.
    PubMed     Abstract available


  743. VALLET S, Fan F, Malvestiti S, Pecherstorfer M, et al
    Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Breast Cancer Res Treat. 2018 Oct 29. pii: 10.1007/s10549-018-5022.
    PubMed     Abstract available


  744. RODRIGUES-FERREIRA S, Nehlig A, Monchecourt C, Nasr S, et al
    Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5026.
    PubMed     Abstract available


  745. CAO S, Zhou J, Zhu Z, Wei F, et al
    Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5016.
    PubMed     Abstract available


  746. WALTER KR, Ford ME, Gregoski MJ, Kramer RM, et al
    Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-4992.
    PubMed     Abstract available


  747. MASKARINEC G, Shvetsov YB, Conroy SM, Haiman CA, et al
    Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort.
    Breast Cancer Res Treat. 2018 Oct 26. pii: 10.1007/s10549-018-5025.
    PubMed     Abstract available


  748. LIU GY, Li JW, Zuo WJ, Ivanova D, et al
    Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5024.
    PubMed     Abstract available


  749. OHARA AM, Naoi Y, Shimazu K, Kagara N, et al
    PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5020.
    PubMed     Abstract available


  750. JONCZYK MM, Jean J, Graham R, Chatterjee A, et al
    Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5018.
    PubMed     Abstract available


  751. CABEL L, Carton M, Cheaib B, Pierga JY, et al
    Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Breast Cancer Res Treat. 2018 Oct 24. pii: 10.1007/s10549-018-5017.
    PubMed     Abstract available


  752. VAN DEN BERG MMGA, Kok DE, Posthuma L, Kamps L, et al
    Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 23. pii: 10.1007/s10549-018-5014.
    PubMed     Abstract available


  753. JEREVALL PL, Brock J, Palazzo J, Wieczorek T, et al
    Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5013.
    PubMed     Abstract available


  754. RYU JM, Choi HJ, Kim I, Nam SJ, et al
    Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5015.
    PubMed     Abstract available


  755. BLANCO C, Markowitz JC, Hellerstein DJ, Nezu AM, et al
    A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4994.
    PubMed     Abstract available


  756. WU T, Sultan LR, Tian J, Cary TW, et al
    Machine learning for diagnostic ultrasound of triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4984.
    PubMed     Abstract available


  757. ALTUNDAG K
    Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-5019.
    PubMed    


  758. HE X, Ji J, Dong R, Liu H, et al
    Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2018 Oct 19. pii: 10.1007/s10549-018-5005.
    PubMed     Abstract available


  759. SOPIK V, Sun P, Narod SA
    Predictors of time to death after distant recurrence in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5002.
    PubMed     Abstract available


  760. LEONARDIS JM, Diefenbach BJ, Lyons DA, Olinger TA, et al
    The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5003.
    PubMed     Abstract available


  761. CAIN EH, Saha A, Harowicz MR, Marks JR, et al
    Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-4990.
    PubMed     Abstract available


  762. FASCHING PA, Hartkopf AD, Gass P, Haberle L, et al
    Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5008.
    PubMed     Abstract available


  763. ALTUNDAG K
    Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5011.
    PubMed    


  764. HWANG HW, Jung H, Hyeon J, Park YH, et al
    A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4981.
    PubMed     Abstract available


  765. TERADA M
    Challenge for identifying the origin of occult breast cancer for optimizing local therapy.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4931.
    PubMed    


  766. INNO A, Barni S, Ghidini A, Zaniboni A, et al
    One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-5001.
    PubMed     Abstract available


  767. ASTASHCHANKA A, Shroka TM, Jacobsen BM
    Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-4989.
    PubMed     Abstract available


  768. HENNIGS A, Kopke M, Feisst M, Riedel F, et al
    Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Breast Cancer Res Treat. 2018 Oct 12. pii: 10.1007/s10549-018-5009.
    PubMed     Abstract available


  769. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Oct 11. pii: 10.1007/s10549-018-4975.
    PubMed     Abstract available


  770. GUESTINI F, Ono K, Miyashita M, Ishida T, et al
    Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4985.
    PubMed     Abstract available


  771. ALFARSI LH, Elansari R, Toss MS, Diez-Rodriguez M, et al
    Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4978.
    PubMed     Abstract available


  772. KUSSAIBI H, Alkharsah KR, Altamimi D, Alsayyah A, et al
    Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4999.
    PubMed     Abstract available


  773. KRAMER CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, et al
    The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
    Breast Cancer Res Treat. 2018 Oct 9. pii: 10.1007/s10549-018-4987.
    PubMed     Abstract available


  774. REN JX, Gong Y, Ling H, Hu X, et al
    Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics.
    Breast Cancer Res Treat. 2018 Oct 6. pii: 10.1007/s10549-018-4956.
    PubMed     Abstract available


  775. JAUCH SF, Riethdorf S, Sprick MR, Schutz F, et al
    Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Oct 1. pii: 10.1007/s10549-018-4972.
    PubMed     Abstract available


  776. JANSEN LE, Teft WA, Rose RV, Lizotte DJ, et al
    CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
    Breast Cancer Res Treat. 2018;171:701-708.
    PubMed     Abstract available


  777. LURASCHI R, Lazzari R, Galimberti V, Rondi E, et al
    Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED).
    Breast Cancer Res Treat. 2018;171:693-699.
    PubMed     Abstract available


  778. COELHO BA, Paiva SPC, da Silva Filho AL
    Extremely brief mindfulness interventions for women undergoing breast biopsies: a randomized controlled trial.
    Breast Cancer Res Treat. 2018;171:685-692.
    PubMed     Abstract available


  779. EULER-CHELPIN MV, Lillholm M, Napolitano G, Vejborg I, et al
    Screening mammography: benefit of double reading by breast density.
    Breast Cancer Res Treat. 2018;171:767-776.
    PubMed     Abstract available


    September 2018
  780. GUCALP A, Traina TA, Eisner JR, Parker JS, et al
    Male breast cancer: a disease distinct from female breast cancer.
    Breast Cancer Res Treat. 2018 Sep 28. pii: 10.1007/s10549-018-4921.
    PubMed     Abstract available


  781. SIMONE BA, Ko K, Simone NL
    Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Sep 27. pii: 10.1007/s10549-018-4940.
    PubMed    


  782. ZUNIGA KE, Parma DL, Munoz E, Spaniol M, et al
    Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4982.
    PubMed     Abstract available


  783. RESNICOW K, Patel MR, Mcleod MC, Katz SJ, et al
    Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4976.
    PubMed     Abstract available


  784. SMETANAY K, Junio P, Feisst M, Seitz J, et al
    COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Sep 25. pii: 10.1007/s10549-018-4983.
    PubMed     Abstract available


  785. XU R, Zhu J
    Association between red and processed meat with breast cancer: Comment on "Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies" by Guo et al.
    Breast Cancer Res Treat. 2018 Sep 24. pii: 10.1007/s10549-018-4977.
    PubMed    


  786. BHARGAVA A, Saha S
    T-Type voltage gated calcium channels: a target in breast cancer?
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4970.
    PubMed     Abstract available


  787. SHEN Y, Fujii T, Ueno NT, Tripathy D, et al
    Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4969.
    PubMed     Abstract available


  788. IWATA H, Masuda N, Yamamoto Y, Fujisawa T, et al
    Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4964.
    PubMed     Abstract available


  789. CHANG E, Mougalian SS, Adelson KB, Young MR, et al
    Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4968.
    PubMed     Abstract available


  790. ACEVEDO F, Armengol VD, Deng Z, Tang R, et al
    Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4962.
    PubMed     Abstract available


  791. LEE SK, Kim SW, Yu JH, Lee JE, et al
    Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4947.
    PubMed     Abstract available


  792. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4944.
    PubMed     Abstract available


  793. NIRAULA S, Gyawali B
    Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4967.
    PubMed     Abstract available


  794. TONG WL, Callahan BM, Tu YN, Zaman S, et al
    Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
    Breast Cancer Res Treat. 2018 Sep 18. pii: 10.1007/s10549-018-4961.
    PubMed     Abstract available


  795. FALATO C, Taylor SK, Szulkin R, Nordblom A, et al
    Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4936.
    PubMed     Abstract available


  796. LIU Z, Sahli Z, Wang Y, Wolff AC, et al
    Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4950.
    PubMed     Abstract available


  797. SPRING L, Niemierko A, Haddad S, Yuen M, et al
    Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
    Breast Cancer Res Treat. 2018 Sep 15. pii: 10.1007/s10549-018-4959.
    PubMed     Abstract available


  798. RYU JM, Choi HJ, Kim I, Lee SK, et al
    Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4948.
    PubMed     Abstract available


  799. KHALED H, Gamal H, Lotayef M, Knauer M, et al
    The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4945.
    PubMed     Abstract available


  800. OLIVA-MORENO J, Pena-Longobardo LM
    Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4963.
    PubMed     Abstract available


  801. JEON SH, Shin KH, Kim JH, Kim K, et al
    Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4966.
    PubMed     Abstract available


  802. PEREZ-PENA J, Gyorffy B, Amir E, Pandiella A, et al
    Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
    Breast Cancer Res Treat. 2018 Sep 11. pii: 10.1007/s10549-018-4965.
    PubMed     Abstract available


  803. TAKADA M, Sugimoto M, Masuda N, Iwata H, et al
    Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
    Breast Cancer Res Treat. 2018 Sep 7. pii: 10.1007/s10549-018-4958.
    PubMed     Abstract available


  804. FENTIMAN IS
    Surgical options for male breast cancer.
    Breast Cancer Res Treat. 2018 Sep 5. pii: 10.1007/s10549-018-4952.
    PubMed     Abstract available


  805. ALTUNDAG K
    Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients.
    Breast Cancer Res Treat. 2018 Sep 3. pii: 10.1007/s10549-018-4949.
    PubMed    


  806. OZAWA PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, et al
    Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
    Breast Cancer Res Treat. 2018 Sep 1. pii: 10.1007/s10549-018-4925.
    PubMed     Abstract available


    August 2018
  807. NAROD SA, Giannakeas V, Sopik V
    Time to death in breast cancer patients as an indicator of treatment response.
    Breast Cancer Res Treat. 2018 Aug 30. pii: 10.1007/s10549-018-4935.
    PubMed     Abstract available


  808. SHEN S, Unger JM, Crew KD, Till C, et al
    Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4946.
    PubMed     Abstract available


  809. MOORE AH, Trentham-Dietz A, Burns M, Gangnon RE, et al
    Obesity and mortality after locoregional breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4932.
    PubMed     Abstract available


  810. ZHANG Z, Li C, Fan H, Xiang Q, et al
    Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4942.
    PubMed     Abstract available


  811. DE SOUZA TIMOTEO AR, Goncalves AEMM, Sales LAP, Albuquerque BM, et al
    A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4938.
    PubMed     Abstract available


  812. THOMAS R, Rowell R, Crichton S, Cain H, et al
    Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4943.
    PubMed     Abstract available


  813. FRONTERA ED, Khansa RM, Schalk DL, Leakan LE, et al
    IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2018 Aug 28. pii: 10.1007/s10549-018-4941.
    PubMed     Abstract available


  814. GOTO-YAMAGUCHI L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, et al
    Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4933.
    PubMed     Abstract available


  815. YANG J, Lv Q
    Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4926.
    PubMed    


  816. ALTUNDAG K
    Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Aug 24. pii: 10.1007/s10549-018-4934.
    PubMed    


  817. BALLINGER TJ, Reddy A, Althouse SK, Nelson EM, et al
    Impact of primary breast cancer therapy on energetic capacity and body composition.
    Breast Cancer Res Treat. 2018 Aug 22. pii: 10.1007/s10549-018-4924.
    PubMed     Abstract available


  818. WANG B, Yuan F
    The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4929.
    PubMed    


  819. BAE SY, Nam SJ, Jung Y, Lee SB, et al
    Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4928.
    PubMed     Abstract available


  820. BEMANIAN V, Noone JC, Sauer T, Touma J, et al
    Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4927.
    PubMed     Abstract available


  821. SONG EJ, Lee CW, Jung SY, Kim BN, et al
    Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4915.
    PubMed     Abstract available


  822. RAMOS J, Das J, Felty Q, Yoo C, et al
    NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Breast Cancer Res Treat. 2018 Aug 20. pii: 10.1007/s10549-018-4905.
    PubMed     Abstract available


  823. CLAESSENS AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, et al
    Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Breast Cancer Res Treat. 2018 Aug 18. pii: 10.1007/s10549-018-4906.
    PubMed     Abstract available


  824. KENN M, Cacsire Castillo-Tong D, Singer CF, Cibena M, et al
    Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
    Breast Cancer Res Treat. 2018 Aug 16. pii: 10.1007/s10549-018-4920.
    PubMed     Abstract available


  825. KRABY MR, Valla M, Opdahl S, Haugen OA, et al
    The prognostic value of androgen receptors in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Aug 14. pii: 10.1007/s10549-018-4904.
    PubMed     Abstract available


  826. BUHL ASK, Christensen TD, Christensen IJ, Nelausen KM, et al
    Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4918.
    PubMed     Abstract available


  827. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4919.
    PubMed     Abstract available


  828. BARBOSA C ROCHA F, Falcone AB, Buzaid AC, Pimenta JM, et al
    Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4912.
    PubMed     Abstract available


  829. GREEN AK, Aviki EM, Matsoukas K, Patil S, et al
    Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4909.
    PubMed     Abstract available


  830. BORRIE AE, Rose RV, Choi YH, Perera FE, et al
    Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4910.
    PubMed     Abstract available


  831. LEE SB, Ko SS, Park CH, Nam SJ, et al
    Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4892.
    PubMed     Abstract available


  832. CHEN BT, Jin T, Patel SK, Ye N, et al
    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4911.
    PubMed     Abstract available


  833. BAE SY, Kim SJ, Lee J, Lee ES, et al
    Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4908.
    PubMed     Abstract available


  834. MURPHY J, Pfeiffer RM, Lynn BCD, Caballero AI, et al
    Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.
    Breast Cancer Res Treat. 2018 Aug 6. pii: 10.1007/s10549-018-4907.
    PubMed     Abstract available


  835. ZDRAVKOVIC D, Nikolic D, Zdravkovic M
    Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?
    Breast Cancer Res Treat. 2018 Aug 4. pii: 10.1007/s10549-018-4913.
    PubMed    


  836. LIN CH, Tang CH
    Rebuttal comments on "Glucocorticoids in breast cancer treatment: Real benefit or selection bias?"
    Breast Cancer Res Treat. 2018 Aug 2. pii: 10.1007/s10549-018-4872.
    PubMed    


    July 2018
  837. SANFT T, Usiskin I, Harrigan M, Cartmel B, et al
    Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4895.
    PubMed     Abstract available


  838. SUN F, Hall A, Tighe MP, Brunelle CL, et al
    Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4902.
    PubMed     Abstract available


  839. FELIZ-MOSQUEA YR, Christensen AA, Wilson AS, Westwood B, et al
    Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4884.
    PubMed     Abstract available


  840. KUROZUMI S, Joseph C, Sonbul S, Aleskandarany MA, et al
    Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4891.
    PubMed     Abstract available


  841. MESSINA C, Cattrini C, Buzzatti G, Cerbone L, et al
    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4901.
    PubMed     Abstract available


  842. LIN JH, Tu SH, Chen LC, Huang CC, et al
    Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4897.
    PubMed     Abstract available


  843. GUNER G, Dizdar O
    Glucocorticoids in breast cancer treatment: real benefit or selection bias?
    Breast Cancer Res Treat. 2018 Jul 26. pii: 10.1007/s10549-018-4871.
    PubMed    


  844. FARSHID G, Walters D
    Molecular subtypes of screen-detected breast cancer.
    Breast Cancer Res Treat. 2018 Jul 25. pii: 10.1007/s10549-018-4899.
    PubMed     Abstract available


  845. MADDEN JM, Murphy L, Zgaga L, Bennett K, et al
    De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4896.
    PubMed     Abstract available


  846. SHARIF-ASKARI B, Amrein L, Aloyz R, Panasci L, et al
    PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4888.
    PubMed     Abstract available


  847. WULANINGSIH W, Garmo H, Ahlgren J, Holmberg L, et al
    Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
    Breast Cancer Res Treat. 2018 Jul 21. pii: 10.1007/s10549-018-4890.
    PubMed     Abstract available


  848. TERADA M, Adachi Y, Sawaki M, Hattori M, et al
    Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Jul 20. pii: 10.1007/s10549-018-4898.
    PubMed     Abstract available


  849. SOLDERA SV, Ennis M, Lohmann AE, Goodwin PJ, et al
    Sexual health in long-term breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jul 19. pii: 10.1007/s10549-018-4894.
    PubMed     Abstract available


  850. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4893.
    PubMed     Abstract available


  851. MCCALL NS, Simone BA, Mehta M, Zhan T, et al
    Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4880.
    PubMed     Abstract available


  852. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jul 16. pii: 10.1007/s10549-018-4883.
    PubMed     Abstract available


  853. VAN NULAND M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, et al
    Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4886.
    PubMed     Abstract available


  854. O'BRIEN KM, Mooney T, Fitzpatrick P, Sharp L, et al
    Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4877.
    PubMed     Abstract available


  855. REDITI M, Messina C
    Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4885.
    PubMed    


  856. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Pantel K, et al
    The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4882.
    PubMed     Abstract available


  857. SAHA A, Harowicz MR, Cain EH, Hall AH, et al
    Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
    Breast Cancer Res Treat. 2018 Jul 10. pii: 10.1007/s10549-018-4879.
    PubMed     Abstract available


  858. NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
    Breast cancer and its impact in male transsexuals.
    Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
    PubMed     Abstract available


  859. ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
    Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
    PubMed     Abstract available


  860. ROBINSON A, Souied O, Bota AB, Levasseur N, et al
    Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
    PubMed     Abstract available


  861. WANG J, Xu B, Wang W, Zhai X, et al
    Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
    PubMed     Abstract available


  862. KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
    Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
    PubMed     Abstract available


  863. BERTHE A, Zaffino M, Muller C, Foulquier F, et al
    Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
    PubMed     Abstract available


  864. SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
    Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
    PubMed     Abstract available


    June 2018
  865. BRENNAN M, Gass P, Haberle L, Wang D, et al
    The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Breast Cancer Res Treat. 2018 Jun 27. pii: 10.1007/s10549-018-4829.
    PubMed     Abstract available


  866. STOUT NK, Cronin AM, Uno H, Ozanne EM, et al
    Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Breast Cancer Res Treat. 2018 Jun 26. pii: 10.1007/s10549-018-4860.
    PubMed     Abstract available


  867. LEE DY, Park YH, Lee JE, Choi D, et al
    Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4863.
    PubMed     Abstract available


  868. VAN SWEARINGEN AED, Siegel MB, Deal AM, Sambade MJ, et al
    LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4852.
    PubMed     Abstract available


  869. YAP YS, Munusamy P, Lim C, Chan CHT, et al
    Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4851.
    PubMed     Abstract available


  870. KIM JY, Lim JE, Jung HH, Cho SY, et al
    Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4858.
    PubMed     Abstract available


  871. BAUER ECA, Schochter F, Widschwendter P, DeGregorio A, et al
    Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4856.
    PubMed     Abstract available


  872. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jun 19. pii: 10.1007/s10549-018-4855.
    PubMed     Abstract available


  873. PEREIRA PTVT, Reis AD, Diniz RR, Lima FA, et al
    Dietary supplements and fatigue in patients with breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4857.
    PubMed     Abstract available


  874. JERZAK KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, et al
    Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4844.
    PubMed     Abstract available


  875. KOGAWA T, Fujii T, Fouad TM, Liu DD, et al
    Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4853.
    PubMed     Abstract available


  876. LI X, Zhang Y, Meisel J, Jiang R, et al
    Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
    Breast Cancer Res Treat. 2018 Jun 15. pii: 10.1007/s10549-018-4832.
    PubMed     Abstract available


  877. LANGBALLE R, Frederiksen K, Jensen MB, Andersson M, et al
    Mortality after contralateral breast cancer in Denmark.
    Breast Cancer Res Treat. 2018 Jun 11. pii: 10.1007/s10549-018-4846.
    PubMed     Abstract available


  878. MANDUJANO-TINOCO EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V, et al
    New emerging roles of microRNAs in breast cancer.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4850.
    PubMed     Abstract available


  879. SMITH BL, Gadd MA, Lanahan CR, Rai U, et al
    Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4845.
    PubMed     Abstract available


  880. LOTSCH J, Sipila R, Tasmuth T, Kringel D, et al
    Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
    Breast Cancer Res Treat. 2018 Jun 6. pii: 10.1007/s10549-018-4841.
    PubMed     Abstract available


  881. KONG AL, Nattinger AB, McGinley E, Pezzin LE, et al
    The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4837.
    PubMed     Abstract available


  882. ROUMELIOTIS M, Long K, Phan T, Graham D, et al
    Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4848.
    PubMed     Abstract available


  883. CHA YJ, Ahn SG, Bae SJ, Yoon CI, et al
    Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4842.
    PubMed     Abstract available


  884. PICADO O, Khazeni K, Allen C, Yakoub D, et al
    Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4840.
    PubMed     Abstract available


  885. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
    PubMed     Abstract available


  886. REDDY JP, Atkinson RL, Larson R, Burks JK, et al
    Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4835.
    PubMed     Abstract available


  887. ARIAS-PULIDO H, Cimino-Mathews A, Chaher N, Qualls C, et al
    The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4834.
    PubMed     Abstract available


  888. EVANS A, Sim YT, Pourreyron C, Thompson A, et al
    Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4836.
    PubMed     Abstract available


    May 2018
  889. JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
    Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
    PubMed     Abstract available


  890. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
    PubMed     Abstract available


  891. JACOB L, Scholten PC, Kostev K, Kalder M, et al
    Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
    PubMed     Abstract available


  892. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
    PubMed     Abstract available


  893. LIU J, Yang Y, Wang H, Wang B, et al
    Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
    PubMed     Abstract available


  894. ELMI M, Sequeira S, Azin A, Elnahas A, et al
    Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
    PubMed     Abstract available


  895. LI D, McCall LM, Hahn OM, Hudis CA, et al
    Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Breast Cancer Res Treat. 2018 May 22. pii: 10.1007/s10549-018-4828.
    PubMed     Abstract available


  896. MASUMOTO N, Kadoya T, Sasada S, Emi A, et al
    Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Breast Cancer Res Treat. 2018 May 19. pii: 10.1007/s10549-018-4791.
    PubMed     Abstract available


  897. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    PubMed     Abstract available


  898. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    PubMed     Abstract available


  899. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    PubMed     Abstract available


  900. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    PubMed     Abstract available


  901. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    PubMed     Abstract available


  902. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    PubMed     Abstract available


  903. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    PubMed     Abstract available


  904. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    PubMed     Abstract available


  905. LOWRY KP, Braunstein LZ, Economopoulos KP, Salama L, et al
    Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4808.
    PubMed     Abstract available


  906. WANG S, Beeghly-Fadiel A, Cai Q, Cai H, et al
    Gene expression in triple-negative breast cancer in relation to survival.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4816.
    PubMed     Abstract available


  907. HUANG Z, Shi Y, Bao P, Cai H, et al
    Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4805.
    PubMed     Abstract available


  908. BARDIA A, Gucalp A, DaCosta N, Gabrail N, et al
    Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4813.
    PubMed     Abstract available


  909. CHOI JY, Cho EY, Choi YJ, Lee JH, et al
    Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4809.
    PubMed     Abstract available


  910. CUI P, Zhao Y, Chu X, He N, et al
    SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4814.
    PubMed     Abstract available


  911. DANIELS B, Kiely BE, Lord SJ, Houssami N, et al
    Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4804.
    PubMed     Abstract available


  912. TELLI ML, Stover DG, Loi S, Aparicio S, et al
    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4807.
    PubMed     Abstract available


  913. TSUNASHIMA R, Naoi Y, Shimazu K, Kagara N, et al
    Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4812.
    PubMed     Abstract available


  914. ABRAHAM J, Coleman R, Elias A, Holmes FA, et al
    Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4783.
    PubMed     Abstract available


  915. WUNDERLE M, Gass P, Haberle L, Flesch VM, et al
    BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Breast Cancer Res Treat. 2018 May 3. pii: 10.1007/s10549-018-4797.
    PubMed     Abstract available


  916. KOMMALAPATI A, Tella SH, Goyal G, Ganti AK, et al
    A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4802.
    PubMed     Abstract available


  917. ERIN N, Ogan N, Yerlikaya A
    Correction to: Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4781.
    PubMed     Abstract available


    April 2018
  918. KIM S, Ko Y, Lee HJ, Lim JE, et al
    Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
    Breast Cancer Res Treat. 2018 Apr 30. pii: 10.1007/s10549-018-4782.
    PubMed     Abstract available


  919. SHIMA H, Kida K, Adachi S, Yamada A, et al
    Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4793.
    PubMed     Abstract available


  920. VOCI A, Lee D, Ho E, Crane-Okada R, et al
    Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4790.
    PubMed     Abstract available


  921. BACHAND J, Soulos PR, Herrin J, Pollack CE, et al
    Physician peer group characteristics and timeliness of breast cancer surgery.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4789.
    PubMed     Abstract available


  922. HAQUE W, Verma V, Hatch S, Suzanne Klimberg V, et al
    Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4801.
    PubMed     Abstract available


  923. SOPIK V, Narod SA
    The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4796.
    PubMed     Abstract available


  924. HACKETT J, Thorneloe R, Side L, Wolf M, et al
    Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4775.
    PubMed     Abstract available


  925. O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
    PubMed     Abstract available


  926. KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
    PubMed     Abstract available


  927. SOARES FALCETTA F, de Araujo Vianna Trasel H, de Almeida FK, Rangel Ribeiro Falcetta M, et al
    Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4786.
    PubMed     Abstract available


  928. VERMA S, O'Shaughnessy J, Burris HA, Campone M, et al
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4769.
    PubMed     Abstract available


  929. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
    Breast Cancer Res Treat. 2018 Apr 12. pii: 10.1007/s10549-018-4784.
    PubMed     Abstract available


  930. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2018 Apr 11. pii: 10.1007/s10549-018-4780.
    PubMed     Abstract available


  931. LARSEN SB, Torstensson M, Kenborg L, Christensen J, et al
    Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 10. pii: 10.1007/s10549-018-4771.
    PubMed     Abstract available


  932. KUROZUMI S, Joseph C, Sonbul S, Gorringe KL, et al
    Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Breast Cancer Res Treat. 2018 Apr 9. pii: 10.1007/s10549-018-4777.
    PubMed     Abstract available


  933. PETROSSIAN K, Nguyen D, Lo C, Kanaya N, et al
    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4779.
    PubMed     Abstract available


  934. CHECK DK, Chawla N, Kwan ML, Pinheiro L, et al
    Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4776.
    PubMed     Abstract available


  935. RAU KM, Ou-Yang F, Chao TC, Kuo YL, et al
    Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4778.
    PubMed     Abstract available


  936. GHILLI M, Mariniello MD, Scatena C, Dosa L, et al
    Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.
    Breast Cancer Res Treat. 2018 Apr 3. pii: 10.1007/s10549-018-4772.
    PubMed     Abstract available


  937. SCHWARTZ MD, Peshkin BN, Isaacs C, Willey S, et al
    Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 2. pii: 10.1007/s10549-018-4773.
    PubMed     Abstract available


    March 2018
  938. MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
    Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
    PubMed     Abstract available


  939. CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
    Validation of a personalized risk prediction model for contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
    PubMed     Abstract available


  940. BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
    PubMed     Abstract available


  941. CAI H, Guo W, Zhang S, Li N, et al
    A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
    PubMed     Abstract available


  942. PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
    Prediction of breast cancer risk with volatile biomarkers in breath.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
    PubMed     Abstract available


  943. RISI E, Grilli A, Migliaccio I, Biagioni C, et al
    A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4766.
    PubMed     Abstract available


  944. AGERSBORG S, Mixon C, Nguyen T, Aithal S, et al
    Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4755.
    PubMed     Abstract available


  945. HILL DA, Friend S, Lomo L, Wiggins C, et al
    Breast cancer survival, survival disparities, and guideline-based treatment.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
    PubMed     Abstract available


  946. DUFFY MJ, Synnott NC, Crown J
    Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4753.
    PubMed     Abstract available


  947. CHATTERJEE S, Chaubal R, Maitra A, Gardi N, et al
    Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4749.
    PubMed     Abstract available


  948. BOYD J
    A parallel model for breast cancer metastasis.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4759.
    PubMed    


  949. SCHAYEK H, Korach H, Laitman Y, Bernstein-Molho R, et al
    Mutational analysis of candidate genes in Israeli male breast cancer cases.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4765.
    PubMed     Abstract available


  950. LI M, Zhou Y, Xia T, Zhou X, et al
    Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4757.
    PubMed     Abstract available


  951. ALTUNDAG K
    Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4762.
    PubMed    


  952. ERIN N, Ogan N, Yerlikaya A
    Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4752.
    PubMed     Abstract available


  953. THONE K, Rudolph A, Obi N, Chang-Claude J, et al
    Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
    Breast Cancer Res Treat. 2018 Mar 19. pii: 10.1007/s10549-018-4754.
    PubMed     Abstract available


  954. KYKER-SNOWMAN K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, et al
    A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4742.
    PubMed     Abstract available


  955. ANGARITA FA, Acuna SA, Cordeiro E, Elnahas A, et al
    Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4747.
    PubMed     Abstract available


  956. BOUYA S, Koochakzai M, Rafiemanesh H, Balouchi A, et al
    Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review.
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4750.
    PubMed     Abstract available


  957. NAROD SA
    Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4739.
    PubMed    


  958. WILSON LE, Pollack CE, Greiner MA, Dinan MA, et al
    Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Breast Cancer Res Treat. 2018 Mar 13. pii: 10.1007/s10549-018-4746.
    PubMed     Abstract available


  959. TURNER TH, Alzubi MA, Sohal SS, Olex AL, et al
    Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Mar 12. pii: 10.1007/s10549-018-4748.
    PubMed     Abstract available


  960. ROY P, Leizorovicz A, Villet R, Mercier C, et al
    Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
    Breast Cancer Res Treat. 2018 Mar 10. pii: 10.1007/s10549-018-4733.
    PubMed     Abstract available


  961. LI Y, Opyrchal M, Yao S, Peng X, et al
    The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Breast Cancer Res Treat. 2018 Mar 9. pii: 10.1007/s10549-018-4745.
    PubMed     Abstract available


  962. BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
    Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
    PubMed     Abstract available


  963. BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
    Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
    PubMed     Abstract available


  964. PARK SJ, Lee MH, Kong SY, Song MK, et al
    Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
    PubMed     Abstract available


  965. VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
    Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
    PubMed     Abstract available


  966. ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
    Preoperative breast MRI and mortality in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
    PubMed     Abstract available


  967. ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
    Exercise and weight loss interventions and miRNA expression in women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
    PubMed     Abstract available


  968. CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
    Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
    PubMed     Abstract available


  969. RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
    Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
    PubMed     Abstract available


    February 2018
  970. GERNAAT SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, et al
    The risk of cardiovascular disease following breast cancer by Framingham risk score.
    Breast Cancer Res Treat. 2018 Feb 28. pii: 10.1007/s10549-018-4723.
    PubMed     Abstract available


  971. KUSHNER CJ, Hwang WT, Wang S, Solin LJ, et al
    Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer.
    Breast Cancer Res Treat. 2018 Feb 27. pii: 10.1007/s10549-018-4729.
    PubMed     Abstract available


  972. CHEN R, Ye Y, Yang C, Peng Y, et al
    Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4730.
    PubMed     Abstract available


  973. BRONTE G, Ravaioli S, Bravaccini S
    What to look for in cell-free DNA from breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4728.
    PubMed    


  974. CHENG J, Burwinkel B
    Cell-free DNA in breast cancer: a long way to go.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4731.
    PubMed    


  975. EBER-SCHULZ P, Tariku W, Reibold C, Addissie A, et al
    Survival of breast cancer patients in rural Ethiopia.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4724.
    PubMed     Abstract available


  976. DE VRIES YC, Boesveldt S, Kelfkens CS, Posthuma EE, et al
    Taste and smell perception and quality of life during and after systemic therapy for breast cancer.
    Breast Cancer Res Treat. 2018 Feb 23. pii: 10.1007/s10549-018-4720.
    PubMed     Abstract available


  977. CLIFTON K, Gutierrez-Barrera A, Ma J, Bassett R Jr., et al
    Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4727.
    PubMed     Abstract available


  978. BAUMANN FT, Reike A, Reimer V, Schumann M, et al
    Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4725.
    PubMed     Abstract available


  979. CHA YJ, Kim ES, Koo JS
    Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4722.
    PubMed     Abstract available


  980. JOHNSON J, Bessette DC, Saunus JM, Smart CE, et al
    Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4719.
    PubMed     Abstract available


  981. RUIZ A, Sebagh M, Wicherts DA, Castro-Benitez C, et al
    Long-term survival and cure model following liver resection for breast cancer metastases.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4714.
    PubMed     Abstract available


  982. RUDOLPH M, Sizemore ST, Lu Y, Teng KY, et al
    A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4718.
    PubMed     Abstract available


  983. WEISS A, Menen RS, Lin HY, Shen Y, et al
    Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4715.
    PubMed     Abstract available


  984. TOT T
    Metastasis of breast cancer prior to invasion.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4721.
    PubMed    


  985. JACOBS DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, et al
    Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4712.
    PubMed     Abstract available


  986. TOLKACH Y, Gevensleben H, Bundschuh R, Koyun A, et al
    Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4717.
    PubMed     Abstract available


  987. WAGNER LI, Zhao F, Goss PE, Chapman JW, et al
    Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4713.
    PubMed     Abstract available


  988. SCHAIRER C, Freedman DM, Gadalla SM, Pfeiffer RM, et al
    Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.
    Breast Cancer Res Treat. 2018 Feb 15. pii: 10.1007/s10549-018-4680.
    PubMed     Abstract available


  989. SHOEMAKER ML, White MC, Wu M, Weir HK, et al
    Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4699.
    PubMed     Abstract available


  990. GIANNAKEAS V, Sopik V, Narod SA
    A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4716.
    PubMed     Abstract available


  991. DEHDASHTI F, Wu N, Bose R, Naughton MJ, et al
    Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4696.
    PubMed     Abstract available


  992. COLLARINO A, Valdes Olmos RA, van Berkel LGAJ, Neijenhuis PA, et al
    The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4706.
    PubMed     Abstract available


  993. CHANG JH, Shin KH, Ahn SD, Park HJ, et al
    Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4707.
    PubMed     Abstract available


  994. HOLLINGSWORTH AB
    Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4702.
    PubMed    


  995. XIE B, Yuan Z, Yang Y, Sun Z, et al
    MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4708.
    PubMed     Abstract available


  996. SKAANE P, Sebuodegard S, Bandos AI, Gur D, et al
    Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4705.
    PubMed     Abstract available


  997. DE MULDER H, Laenen A, Wildiers H, Punie K, et al
    Breast cancer subtype and survival by parity and time since last birth.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4701.
    PubMed     Abstract available


  998. MIYAKE KK, Nakamoto Y, Saji S, Sugie T, et al
    Impact of physiological hormonal fluctuations on (18)F-fluorodeoxyglucose uptake in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4711.
    PubMed     Abstract available


  999. GOLDVASER H, Majeed H, Ribnikar D, Seruga B, et al
    Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4710.
    PubMed     Abstract available


  1000. COSTA RLB, Han HS, Gradishar WJ
    Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Breast Cancer Res Treat. 2018 Feb 7. pii: 10.1007/s10549-018-4697.
    PubMed     Abstract available


  1001. ZAREI N, Fazeli M, Mohammadi M, Nejatollahi F, et al
    Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
    Breast Cancer Res Treat. 2018 Feb 6. pii: 10.1007/s10549-017-4641.
    PubMed     Abstract available


  1002. LAMMERT J, Lubinski J, Gronwald J, Huzarski T, et al
    Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-018-4694.
    PubMed     Abstract available


  1003. JANNI W, Alba E, Bachelot T, Diab S, et al
    First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-017-4658.
    PubMed     Abstract available


  1004. VALDORA F, Houssami N, Rossi F, Calabrese M, et al
    Rapid review: radiomics and breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-018-4675.
    PubMed     Abstract available


  1005. FOLDI J, Mougalian S, Silber A, Lannin D, et al
    Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-017-4653.
    PubMed     Abstract available


  1006. ZHOU S, Wang L, Yang Q, Liu H, et al
    Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4678.
    PubMed     Abstract available


  1007. MATOSSIAN MD, Burks HE, Bowles AC, Elliott S, et al
    A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4685.
    PubMed     Abstract available


    January 2018
  1008. LEE SB, Sohn G, Kim J, Chung IY, et al
    A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Breast Cancer Res Treat. 2018 Jan 31. pii: 10.1007/s10549-018-4682.
    PubMed     Abstract available


  1009. HWANG KT, Kim EK, Jung SH, Lee ES, et al
    Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Breast Cancer Res Treat. 2018 Jan 30. pii: 10.1007/s10549-018-4681.
    PubMed     Abstract available


  1010. JANSSON S, Aaltonen K, Bendahl PO, Falck AK, et al
    The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Breast Cancer Res Treat. 2018 Jan 29. pii: 10.1007/s10549-018-4664.
    PubMed     Abstract available


  1011. FAIRWEATHER M, Jiang W, Keating NL, Freedman RA, et al
    Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry.
    Breast Cancer Res Treat. 2018 Jan 27. pii: 10.1007/s10549-018-4689.
    PubMed     Abstract available


  1012. ZHANG L, Yu Q, Wu XC, Hsieh MC, et al
    Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-017-4646.
    PubMed     Abstract available


  1013. GOYAL NG, Levine BJ, Van Zee KJ, Naftalis E, et al
    Trajectories of quality of life following breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-018-4677.
    PubMed     Abstract available


  1014. POURCELOT C, Orillard E, Nallet G, Dirand C, et al
    Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
    Breast Cancer Res Treat. 2018 Jan 23. pii: 10.1007/s10549-018-4676.
    PubMed     Abstract available


  1015. FAN Z, Ouyang T, Li J, Wang T, et al
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Jan 22. pii: 10.1007/s10549-018-4673.
    PubMed     Abstract available


  1016. JONES T, Duquette D, Underhill M, Ming C, et al
    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-018-4674.
    PubMed     Abstract available


  1017. NAROD SA, Sopik V
    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-017-4644.
    PubMed     Abstract available


  1018. BAO T, Seidman A, Li Q, Seluzicki C, et al
    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4670.
    PubMed     Abstract available


  1019. ABRAHAM J, Caldera H, Coleman R, Elias A, et al
    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4662.
    PubMed     Abstract available


  1020. MIJWEL S, Backman M, Bolam KA, Olofsson E, et al
    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4663.
    PubMed     Abstract available


  1021. PEDERSON HJ, Hussain N, Noss R, Yanda C, et al
    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-017-4643.
    PubMed     Abstract available


  1022. KOOPMAN T, Buikema HJ, Hollema H, de Bock GH, et al
    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4669.
    PubMed     Abstract available


  1023. BREYER JZ, Wendland EM, Kops NL, Caleffi M, et al
    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat. 2018 Jan 17. pii: 10.1007/s10549-017-4655.
    PubMed     Abstract available


  1024. GARCIA GARRE E, Luengo Gil G, Montoro Garcia S, Gonzalez Billalabeitia E, et al
    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4656.
    PubMed     Abstract available


  1025. CHENG J, Holland-Letz T, Wallwiener M, Surowy H, et al
    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-018-4666.
    PubMed     Abstract available


  1026. NI YB, Tsang JYS, Shao MM, Chan SK, et al
    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4645.
    PubMed     Abstract available


  1027. FOSTIRA F, Saloustros E, Apostolou P, Vagena A, et al
    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-018-4661.
    PubMed     Abstract available


  1028. JAKIMOVSKA M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, et al
    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4642.
    PubMed     Abstract available


  1029. LAMBERTINI M, Fontanella C
    How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4654.
    PubMed    


  1030. POORVU PD, Vaz-Luis I, Freedman RA, Lin NU, et al
    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4659.
    PubMed     Abstract available


  1031. ZHANG Y, Ji Y, Li J, Lei L, et al
    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4660.
    PubMed     Abstract available


  1032. PAN K, Hurria A, Chlebowski RT
    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-017-4650.
    PubMed     Abstract available


  1033. PAN Y, Heisig SR, von Blanckenburg P, Albert US, et al
    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4637.
    PubMed     Abstract available


  1034. NUNCIA-CANTARERO M, Martinez-Canales S, Andres-Pretel F, Santpere G, et al
    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4652.
    PubMed     Abstract available


  1035. TAN Q, Wei C
    Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4648.
    PubMed    


  1036. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 11. pii: 10.1007/s10549-017-4634.
    PubMed     Abstract available



  1037. 1st UK Interdisciplinary Breast Cancer Symposium-15th-16th January 2018.
    Breast Cancer Res Treat. 2018 Jan 10. pii: 10.1007/s10549-017-4585.
    PubMed    


  1038. LILJEGREN A, von Wachenfeldt A, Azavedo E, Eloranta S, et al
    Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Breast Cancer Res Treat. 2018 Jan 9. pii: 10.1007/s10549-017-4639.
    PubMed     Abstract available


  1039. CHAE JW, Chua PS, Ng T, Yeo AHL, et al
    Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Breast Cancer Res Treat. 2018 Jan 8. pii: 10.1007/s10549-017-4640.
    PubMed     Abstract available


  1040. BRAVACCINI S, Rocca A, Bronte G
    Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 6. pii: 10.1007/s10549-017-4630.
    PubMed    


  1041. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 5. pii: 10.1007/s10549-017-4633.
    PubMed     Abstract available


  1042. WANG S, Qian F, Zheng Y, Ogundiran T, et al
    Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    Breast Cancer Res Treat. 2018 Jan 4. pii: 10.1007/s10549-017-4638.
    PubMed     Abstract available


  1043. KOSTEV K, Kalder M
    20-year risk of breast cancer recurrence.
    Breast Cancer Res Treat. 2018 Jan 3. pii: 10.1007/s10549-017-4636.
    PubMed    


    December 2017
  1044. HADDAD TC, D'Assoro A, Suman V, Opyrchal M, et al
    Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 30. pii: 10.1007/s10549-017-4616.
    PubMed     Abstract available


  1045. PONDE N, Bradbury I, Lambertini M, Ewer M, et al
    Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Breast Cancer Res Treat. 2017 Dec 27. pii: 10.1007/s10549-017-4628.
    PubMed     Abstract available


  1046. KOSTEV K, Kalder M
    Long-term use of basal insulin and the risk of breast cancer.
    Breast Cancer Res Treat. 2017 Dec 26. pii: 10.1007/s10549-017-4631.
    PubMed    


  1047. TELLI ML, Hellyer J, Audeh W, Jensen KC, et al
    Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Breast Cancer Res Treat. 2017 Dec 23. pii: 10.1007/s10549-017-4624.
    PubMed     Abstract available


  1048. FAZZINO TL, Klemp J, Befort C
    Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.
    Breast Cancer Res Treat. 2017 Dec 22. pii: 10.1007/s10549-017-4603.
    PubMed     Abstract available


  1049. PICHILINGUE-FEBRES AF, Arias-Linares MA, Araujo-Castillo RV
    Comments on "Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors" by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat. 2017 Dec 21. pii: 10.1007/s10549-017-4620.
    PubMed     Abstract available


  1050. UNDERWOOD EA, Rochon PA, Moineddin R, Lee PE, et al
    Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2017 Dec 20. pii: 10.1007/s10549-017-4627.
    PubMed     Abstract available


  1051. DUGGAN C, Baumgartner RN, Baumgartner KB, Bernstein L, et al
    Genetic variation in TNFalpha, PPARgamma, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4621.
    PubMed     Abstract available


  1052. VAN SEIJEN M, Mooyaart AL, Mulder L, Hoogstraat M, et al
    Enrichment of high-grade tumors in breast cancer gene expression studies.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4622.
    PubMed     Abstract available


  1053. KWAN ML, Yao S, Laurent CA, Roh JM, et al
    Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2017 Dec 16. pii: 10.1007/s10549-017-4626.
    PubMed     Abstract available


  1054. DU RUSQUEC P, Palpacuer C, Campion L, Patsouris A, et al
    Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4623.
    PubMed     Abstract available


  1055. NAROD SA, Huzarski T, Gronwald J, Byrski T, et al
    Predictors of survival for breast cancer patients with a BRCA1 mutation.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4605.
    PubMed     Abstract available


  1056. ZIMMER AS, Zhu K, Steeg PS, Wu A, et al
    Analysis of breast cancer in young women in the Department of Defense (DOD) database.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4615.
    PubMed     Abstract available


  1057. FALANDRY C, Krakowski I, Cure H, Carola E, et al
    Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.
    Breast Cancer Res Treat. 2017 Dec 14. pii: 10.1007/s10549-017-4607.
    PubMed     Abstract available


  1058. FANG H, Huang D, Yang F, Guan X, et al
    Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Dec 13. pii: 10.1007/s10549-017-4612.
    PubMed     Abstract available


  1059. HAN SN, Amant F, Cardonick EH, Loibl S, et al
    Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4611.
    PubMed     Abstract available


  1060. BENS A, Papadopoulos FC, Pukkala E, Ekbom A, et al
    Worse survival after breast cancer in women with anorexia nervosa.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4618.
    PubMed     Abstract available


  1061. VAN VULPEN JK, Schmidt ME, Velthuis MJ, Wiskemann J, et al
    Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4608.
    PubMed     Abstract available


  1062. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4601.
    PubMed     Abstract available


  1063. SPEIGL L, Burow H, Bailur JK, Janssen N, et al
    CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4594.
    PubMed     Abstract available


  1064. XIE J, Cao J, Wang JF, Zhang BH, et al
    Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4609.
    PubMed     Abstract available


  1065. SINGH K, He X, Kalife ET, Ehdaivand S, et al
    Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4619.
    PubMed     Abstract available


  1066. LI W, Kwok CC, Chan DC, Wang F, et al
    Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4614.
    PubMed     Abstract available


  1067. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4578.
    PubMed     Abstract available


  1068. IBRAHIM MFK, Hilton J, Mazzarello S, Fergusson D, et al
    A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4604.
    PubMed     Abstract available


  1069. WANG J, Fan T, He Y, Chen X, et al
    (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4591.
    PubMed     Abstract available


  1070. PISTILLI B, Pluard T, Urruticoechea A, Farci D, et al
    Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Breast Cancer Res Treat. 2017 Dec 2. pii: 10.1007/s10549-017-4596.
    PubMed     Abstract available


    November 2017
  1071. REINERT T, Debiasi M, Bines J, Barrios CH, et al
    Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4593.
    PubMed     Abstract available


  1072. XIA Z, Baumgartner KB, Baumgartner RN, Boone SD, et al
    Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4600.
    PubMed     Abstract available


  1073. MATIKAS A, Margolin S, Hellstrom M, Johansson H, et al
    Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4599.
    PubMed     Abstract available


  1074. YU YF, Wang Y, Fu TP, Chen K, et al
    Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 29. pii: 10.1007/s10549-017-4592.
    PubMed     Abstract available


  1075. WANG Z, Kong J, Wu Y, Zhang J, et al
    PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4597.
    PubMed     Abstract available


  1076. TRENTHAM-DIETZ A, Ergun MA, Alagoz O, Stout NK, et al
    Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4582.
    PubMed     Abstract available


  1077. LOHRISCH C, Francl M, Sun S, Villa D, et al
    Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
    Breast Cancer Res Treat. 2017 Nov 27. pii: 10.1007/s10549-017-4586.
    PubMed     Abstract available


  1078. VILLEGAS SL, Darb-Esfahani S, von Minckwitz G, Huober J, et al
    Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2017 Nov 25. pii: 10.1007/s10549-017-4581.
    PubMed     Abstract available


  1079. LIU YL, Connolly EP, Kalinsky K
    Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4590.
    PubMed    


  1080. PEZO RC, Chen TW, Berman HK, Mulligan AM, et al
    Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4580.
    PubMed     Abstract available


  1081. ALTUNDAG K
    Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4589.
    PubMed    


  1082. COLOMER R, Hall P, Szkultecka-Debek M, Bondi RC, et al
    Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Breast Cancer Res Treat. 2017 Nov 23. pii: 10.1007/s10549-017-4567.
    PubMed     Abstract available


  1083. LECLERC M, Neuhausen SL, Schayek H, Laitman Y, et al
    Are VNTRs co-localizing with breast cancer-associated SNPs?
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4588.
    PubMed     Abstract available


  1084. DIELI-CONWRIGHT CM, Parmentier JH, Sami N, Lee K, et al
    Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention.
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4576.
    PubMed     Abstract available


  1085. O'SHAUGHNESSY J, Petrakova K, Sonke GS, Conte P, et al
    Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4518.
    PubMed     Abstract available


  1086. NILSSON MP, Torngren T, Henriksson K, Kristoffersson U, et al
    BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4584.
    PubMed     Abstract available


  1087. ASLEH K, Won JR, Gao D, Voduc KD, et al
    Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4583.
    PubMed     Abstract available


  1088. BROUCKAERT O, Van Asten K, Laenen A, Soubry A, et al
    Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4579.
    PubMed     Abstract available


  1089. RIER HN, Jager A, Sleijfer S, van Rosmalen J, et al
    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574.
    PubMed     Abstract available


  1090. ABDEL-RAHMAN O
    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat. 2017 Nov 15. doi: 10.1007/s10549-017-4577.
    PubMed     Abstract available


  1091. MIJWEL S, Backman M, Bolam KA, Jervaeus A, et al
    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4571.
    PubMed     Abstract available


  1092. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4568.
    PubMed     Abstract available


  1093. MENESES K, Benz R, Bail JR, Vo JB, et al
    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4564.
    PubMed     Abstract available


  1094. DODSON A, Okonji D, Assersohn L, Rigg A, et al
    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514.
    PubMed     Abstract available


  1095. BOSTNER J, Alayev A, Berman AY, Fornander T, et al
    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4508.
    PubMed     Abstract available


  1096. GILLMAN AS, Gardiner CK, Koljack CE, Bryan AD, et al
    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4573.
    PubMed     Abstract available


  1097. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4569.
    PubMed     Abstract available


  1098. KWA M, Li X, Novik Y, Oratz R, et al
    Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570.
    PubMed     Abstract available


  1099. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4565.
    PubMed     Abstract available


  1100. LYNCE F, Blackburn MJ, Cai L, Wang H, et al
    Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4563.
    PubMed     Abstract available


  1101. SOPIK V, Sun P, Narod SA
    Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4572.
    PubMed     Abstract available


  1102. BRIANESE RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, et al
    BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4552.
    PubMed     Abstract available


  1103. EVANS DG, Harkness EF, Howel S, Woodward ER, et al
    Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4557.
    PubMed     Abstract available


  1104. GOING CC, Alexandrova L, Lau K, Yeh CY, et al
    Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4562.
    PubMed     Abstract available


  1105. MURPHY BL, Zalewski NL, Degnim AC, McKeon A, et al
    Breast cancer-related paraneoplastic neurologic disease.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4566.
    PubMed     Abstract available


  1106. RIMAWI MF, De Angelis C, Contreras A, Pareja F, et al
    Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4533.
    PubMed     Abstract available


  1107. LAMBERT LK, Balneaves LG, Howard AF, Gotay CC, et al
    Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4561.
    PubMed     Abstract available


  1108. KIRKHAM AA, Eves ND, Shave RE, Bland KA, et al
    The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4554.
    PubMed     Abstract available


  1109. FREEDMAN RA, Tolaney SM
    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast Cancer Res Treat. 2017 Nov 4. doi: 10.1007/s10549-017-4560.
    PubMed     Abstract available


  1110. RODRIGUEZ-WALLBERG KA, Eloranta S, Krawiec K, Lissmats A, et al
    Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Breast Cancer Res Treat. 2017 Nov 2. doi: 10.1007/s10549-017-4555.
    PubMed     Abstract available


    October 2017
  1111. NGUYEN F, Pena L, Ibisch C, Loussouarn D, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4548.
    PubMed     Abstract available


  1112. RABOW M, Small R, Jow A, Majure M, et al
    The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4556.
    PubMed     Abstract available


  1113. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Oct 25. doi: 10.1007/s10549-017-4539.
    PubMed     Abstract available


  1114. BOCK CH, Jay AM, Dyson G, Beebe-Dimmer JL, et al
    The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.
    Breast Cancer Res Treat. 2017 Oct 24. doi: 10.1007/s10549-017-4521.
    PubMed     Abstract available


  1115. DIRIX LY, Takacs I, Jerusalem G, Nikolinakos P, et al
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4537.
    PubMed     Abstract available


  1116. ABADIE J, Nguyen F, Loussouarn D, Pena L, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4542.
    PubMed     Abstract available


  1117. ALTUNDAG K
    Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4544.
    PubMed    


  1118. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4541.
    PubMed     Abstract available


  1119. SONKE GS, Hart LL, Campone M, Erdkamp F, et al
    Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Oct 22. doi: 10.1007/s10549-017-4523.
    PubMed     Abstract available


  1120. TAN Q, Qin Q
    Does the elevation of CAMLs predict metastatic breast cancer patients' survival?
    Breast Cancer Res Treat. 2017 Oct 20. doi: 10.1007/s10549-017-4546.
    PubMed    


  1121. MORDANG JJ, Gubern-Merida A, Bria A, Tortorella F, et al
    The importance of early detection of calcifications associated with breast cancer in screening.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4527.
    PubMed     Abstract available


  1122. LUBINSKI J, Marciniak W, Muszynska M, Huzarski T, et al
    Serum selenium levels predict survival after breast cancer.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4525.
    PubMed     Abstract available


  1123. MALMGREN JA, Mayer M, Atwood MK, Kaplan HG, et al
    Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4529.
    PubMed     Abstract available


  1124. SCHON K, Tischkowitz M
    Clinical implications of germline mutations in breast cancer: TP53.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4531.
    PubMed     Abstract available


  1125. FIETZ T, Zahn MO, Kohler A, Engel E, et al
    Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4534.
    PubMed     Abstract available


  1126. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4530.
    PubMed     Abstract available


  1127. BERNSTEIN V, Ellard SL, Dent SF, Tu D, et al
    A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4538.
    PubMed     Abstract available


  1128. ADACHI Y, Yoshimura M, Nishida K, Usuki H, et al
    Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
    Breast Cancer Res Treat. 2017 Oct 12. doi: 10.1007/s10549-017-4532.
    PubMed     Abstract available


  1129. ALTUNDAG K
    Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
    Breast Cancer Res Treat. 2017 Oct 11. doi: 10.1007/s10549-017-4536.
    PubMed    


  1130. DOMINICI LS, Sineshaw HM, Jemal A, Lin CC, et al
    Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Breast Cancer Res Treat. 2017 Oct 9. doi: 10.1007/s10549-017-4528.
    PubMed     Abstract available


  1131. PAGE DB, Wen H, Brogi E, Dure D, et al
    Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Breast Cancer Res Treat. 2017 Oct 6. doi: 10.1007/s10549-017-4520.
    PubMed     Abstract available


  1132. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Abstract available


    September 2017
  1133. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Abstract available


  1134. GALLARDO A, Lerma E
    Response letter to: Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4524.
    PubMed    


  1135. ALTUNDAG K
    Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4515.
    PubMed    


  1136. LUU T, Kim KP, Blanchard S, Anyang B, et al
    Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516.
    PubMed     Abstract available


  1137. TSOUTSOU PG, Durham AD, Vozenin MC
    A need for biology-driven personalized radiotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4522.
    PubMed    


  1138. SAYED S, Moloo Z, Wasike R, Bird P, et al
    Ethnicity and breast cancer characteristics in Kenya.
    Breast Cancer Res Treat. 2017 Sep 26. doi: 10.1007/s10549-017-4511.
    PubMed     Abstract available


  1139. LIU YL, Saraf A, Catanese B, Lee SM, et al
    Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4507.
    PubMed     Abstract available


  1140. CRONIN-FENTON D, Kjaersgaard A, Norgaard M, Amelio J, et al
    Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4510.
    PubMed     Abstract available


  1141. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Erratum to: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Sep 20. doi: 10.1007/s10549-017-4505.
    PubMed     Abstract available


  1142. RICE BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, et al
    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat. 2017 Sep 18. doi: 10.1007/s10549-017-4506.
    PubMed     Abstract available


  1143. JEONG IJ, Lee SG, Kim YH, Ko BS, et al
    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4504.
    PubMed     Abstract available


  1144. GIANNAKEAS V, Narod SA
    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4476.
    PubMed     Abstract available


  1145. LEON-FERRE RA, Polley MY, Liu H, Gilbert JA, et al
    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499.
    PubMed     Abstract available


  1146. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4501.
    PubMed     Abstract available


  1147. SIEGELMANN-DANIELI N, Katzir I, Landes JV, Segal Y, et al
    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491.
    PubMed     Abstract available


  1148. KOCHI M, Iwamoto T, Niikura N, Bianchini G, et al
    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4502.
    PubMed     Abstract available


  1149. MASUNAGA N, Kagara N, Motooka D, Nakamura S, et al
    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4487.
    PubMed     Abstract available


  1150. ROCQUE GB, Williams CP, Jones MI, Kenzik KM, et al
    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat. 2017 Sep 12. doi: 10.1007/s10549-017-4498.
    PubMed     Abstract available


  1151. NIIKURA N, Shimomura A, Fukatsu Y, Sawaki M, et al
    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4489.
    PubMed     Abstract available


  1152. GREGOROWITSCH ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, et al
    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495.
    PubMed     Abstract available


  1153. SAUNUS JM, Smart CE, Kutasovic JR, Johnston RL, et al
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat. 2017 Sep 9. doi: 10.1007/s10549-017-4496.
    PubMed     Abstract available


    August 2017
  1154. WEBER WP, Soysal SD, El-Tamer M, Sacchini V, et al
    First international consensus conference on standardization of oncoplastic breast conserving surgery.
    Breast Cancer Res Treat. 2017;165:139-149.
    PubMed     Abstract available


  1155. CONT NT, Maggiorotto F, Martincich L, Rivolin A, et al
    Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.
    Breast Cancer Res Treat. 2017;165:85-95.
    PubMed     Abstract available


    June 2017
  1156. SANTEN RJ, Radisky DC, Degnim A, Frost MH, et al
    Aromatase expression in atypical ductal hyperplasia in women.
    Breast Cancer Res Treat. 2017;163:623-629.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: